191 results on '"Sabrina M. Ronen"'
Search Results
52. Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology
- Author
-
Kayvan R. Keshari, Andreas Kjaer, Rahim R. Rizi, Jan Henrik Ardenkjær-Larsen, Craig R. Malloy, Charles H. Cunningham, David A. Mankoff, Matthew E. Merritt, Sabrina M. Ronen, Daniel M. Spielman, Philip Lee, Ferdia A. Gallagher, Lawrence L. Wald, Sarah J. Nelson, Damian J. Tyler, Kevin M. Brindle, John M. Pauly, Xiaoliang Zhang, Christoffer Laustsen, James A. Bankson, Daniel B. Vigneron, John Kurhanewicz, Sunder S. Rajan, Brindle, Kevin [0000-0003-3883-6287], Gallagher, Ferdia [0000-0003-4784-5230], and Apollo - University of Cambridge Repository
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,Biomedical ,Magnetic Resonance Imaging/methods ,Translational Research, Biomedical ,Prostate cancer ,0302 clinical medicine ,White paper ,Neoplasms ,Hyperpolarization (physics) ,Translational Medical Research ,Cancer ,screening and diagnosis ,Carbon Isotopes ,medicine.diagnostic_test ,Prostate Cancer ,Hyperpolarized 13c ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Magnetic Resonance Imaging ,Detection ,030220 oncology & carcinogenesis ,Biomedical Imaging ,Urologic Diseases ,medicine.medical_specialty ,Clinical Trials and Supportive Activities ,Clinical Sciences ,Bioengineering ,lcsh:RC254-282 ,03 medical and health sciences ,Review article ,SDG 3 - Good Health and Well-being ,Clinical Research ,Internal medicine ,Translational Research ,medicine ,Animals ,Humans ,In patient ,Oncology & Carcinogenesis ,Modalities ,business.industry ,Animal ,Reproducibility of Results ,Magnetic resonance imaging ,medicine.disease ,4.1 Discovery and preclinical testing of markers and technologies ,Disease Models, Animal ,030104 developmental biology ,Cancer metabolism ,Disease Models ,business ,Digestive Diseases ,Neoplasms/diagnosis - Abstract
This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging’s (MRI’s) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.
- Published
- 2019
53. NIMG-51. DEUTERIUM METABOLIC IMAGING OF BRAIN TUMOR IMMORTALITY USING 2H-PYRUVATE
- Author
-
Meryssa Tran, Georgios Batsios, Céline Taglang, Anne Marie Gillespie, Sabrina M. Ronen, Pavithra Viswanath, and Joseph F. Costello
- Subjects
Cancer Research ,Telomerase ,Chemistry ,Somatic cell ,Brain tumor ,26th Annual Meeting & Education Day of the Society for Neuro-Oncology ,medicine.disease ,chemistry.chemical_compound ,Oncology ,Neuroimaging ,Glioma ,Medical imaging ,medicine ,Cancer research ,Deoxyguanosine ,Neurology (clinical) ,Oligodendroglioma - Abstract
Telomere maintenance is essential for tumor immortality and sustained tumor proliferation. Most tumors, including high-grade glioblastomas and low-grade oligodendrogliomas achieve telomere maintenance via reactivation of the expression of telomerase reverse transcriptase (TERT), which is silenced in normal somatic cells. Due to this essential role, TERT is a therapeutic target and TERT inhibitors such as 6-thio-2’-deoxyguanosine are in clinical trials. Non-invasive methods of imaging TERT, therefore, have the potential to provide a readout of tumor proliferation and response to therapy. We previously showed that TERT expression is associated with elevated levels of NADH in gliomas. Since NADH is essential for the conversion of pyruvate to lactate, measuring pyruvate flux to lactate could be useful for imaging TERT expression. In this context, deuterium magnetic resonance spectroscopy (2H-MRS) recently emerged as a novel, clinically translatable method of monitoring metabolic fluxes. The goal of this study was to assess the potential of [U-2H]pyruvate for non-invasive imaging of TERT status in gliomas. Following intravenous injection of [U-2H]pyruvate, lactate production was significantly higher in mice bearing orthotopic oligodendroglioma (SF10417, BT88) or glioblastoma (GBM1, GBM6) tumors relative to tumor-free controls. 2D chemical shift imaging showed localization of lactate production to tumor vs. contralateral normal brain. Importantly, following treatment of mice bearing orthotopic GBM6 or BT88 tumors with the TERT inhibitor 6-thio-2’-deoxyguanosine, lactate production from [U-2H]pyruvate was significantly reduced at early timepoints when alterations in tumor volume could not be detected by anatomical imaging, pointing to the ability of [U-2H]pyruvate to report on pseudoprogression. Collectively, we have, for the first time, demonstrated the utility of [U-2H]pyruvate for metabolic imaging of brain tumor burden and treatment response in vivo. Importantly, since 2H-MRS can be implemented on clinical scanners, our results provide a novel, non-invasive method of integrating information regarding a fundamental tumor hallmark, i.e. TERT, into glioma patient management.
- Published
- 2021
54. Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas
- Author
-
Pavithra Viswanath, Joseph F. Costello, Anne Marie Gillespie, Georgios Batsios, Peder E. Z. Larson, Sabrina M. Ronen, Vinay Ayyappan, Russell O. Pieper, H. Artee Luchman, and Céline Taglang
- Subjects
hyperpolarized C-13 ,Cancer Research ,Telomerase ,Magnetic Resonance Spectroscopy ,glucose metabolism ,Oncology and Carcinogenesis ,Oligodendroglioma ,Pentose phosphate pathway ,telomerase ,SIRT2 ,Pentose Phosphate Pathway ,Rare Diseases ,Clinical Research ,Glioma ,medicine ,Humans ,Telomerase reverse transcriptase ,Oncology & Carcinogenesis ,Cancer ,hyperpolarized 13C ,biology ,Chemistry ,Neurosciences ,Glucose transporter ,Metabolism ,medicine.disease ,Brain Disorders ,gliomas ,Brain Cancer ,Glucose ,Oncology ,Basic and Translational Investigations ,biology.protein ,Cancer research ,GLUT1 ,Neurology (clinical) - Abstract
Background Telomerase reverse transcriptase (TERT) is essential for tumor proliferation, including in low-grade oligodendrogliomas (LGOGs). Since TERT is silenced in normal cells, it is also a therapeutic target. Therefore, noninvasive methods of imaging TERT are needed. Here, we examined the link between TERT expression and metabolism in LGOGs, with the goal of leveraging this information for noninvasive magnetic resonance spectroscopy (MRS)-based metabolic imaging of LGOGs. Methods Immortalized normal human astrocytes with doxycycline-inducible TERT silencing, patient-derived LGOG cells, orthotopic tumors, and LGOG patient biopsies were studied to determine the mechanistic link between TERT expression and glucose metabolism. The ability of hyperpolarized [U-13C, U-2H]-glucose to noninvasively assess TERT expression was tested in live cells and orthotopic tumors. Results TERT expression was associated with elevated glucose flux through the pentose phosphate pathway (PPP), elevated NADPH, which is a major product of the PPP, and elevated glutathione, which is maintained in a reduced state by NADPH. Importantly, hyperpolarized [U-13C, U-2H]-glucose metabolism via the PPP noninvasively reported on TERT expression and response to TERT inhibition in patient-derived LGOG cells and orthotopic tumors. Mechanistically, TERT acted via the sirtuin SIRT2 to upregulate the glucose transporter GLUT1 and the rate-limiting PPP enzyme glucose-6-phosphate dehydrogenase. Conclusions We have, for the first time, leveraged a mechanistic understanding of TERT-associated metabolic reprogramming for noninvasive imaging of LGOGs using hyperpolarized [U-13C, U-2H]-glucose. Our findings provide a novel way of imaging a hallmark of tumor immortality and have the potential to improve diagnosis and treatment response assessment for LGOG patients.
- Published
- 2021
55. Imaging 6-Phosphogluconolactonase Activity in Brain Tumors In Vivo Using Hyperpolarized δ-[1-13C]gluconolactone
- Author
-
Peng Cao, Georgios Batsios, Chloé Najac, Peder E. Z. Larson, Elavarasan Subramani, Céline Taglang, Sabrina M. Ronen, Robert R. Flavell, Pavithra Viswanath, Anne Marie Gillespie, and David M. Wilson
- Subjects
Cancer Research ,Oncology and Carcinogenesis ,pentose phosphate pathway ,Pentose phosphate pathway ,medicine.disease_cause ,I) ,lcsh:RC254-282 ,Gluconolactone ,6-phosphogluconolactonase ,dynamic nuclear polarization ,chemistry.chemical_compound ,pentose phosphate pathway (PPP) ,dynamic nuclear polarization (DNP) ,Rare Diseases ,In vivo ,magnetic resonance spectroscopy/imaging ,medicine ,hyperpolarized 13C MRS ,magnetic resonance spectroscopy/imaging (MRS/I) ,Cancer ,Gene knockdown ,Temozolomide ,Chemistry ,glioblastoma ,Neurosciences ,Glutathione ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,magnetic resonance spectroscopy ,metabolic therapy ,Brain Disorders ,Brain Cancer ,Oncology ,Cancer research ,brain tumors ,Biomedical Imaging ,imaging (MRS ,hyperpolarized C-13 MRS ,Preclinical imaging ,Oxidative stress ,medicine.drug - Abstract
IntroductionThe pentose phosphate pathway (PPP) is essential for NADPH generation and redox homeostasis in cancer, including glioblastomas. However, the precise contribution to redox and tumor proliferation of the second PPP enzyme 6-phosphogluconolactonase (PGLS), which converts 6-phospho-δ-gluconolactone to 6-phosphogluconate (6PG), remains unclear. Furthermore, non-invasive methods of assessing PGLS activity are lacking. The goal of this study was to examine the role of PGLS in glioblastomas and assess the utility of probing PGLS activity using hyperpolarized δ-[1-13C]gluconolactone for non-invasive imaging.MethodsTo interrogate the function of PGLS in redox, PGLS expression was silenced in U87, U251 and GS2 glioblastoma cells by RNA interference and levels of NADPH and reduced glutathione (GSH) measured. Clonogenicity assays were used to assess the effect of PGLS silencing on glioblastoma proliferation. Hyperpolarized δ-[1-13C]gluconolactone metabolism to 6PG was assessed in live cells treated with the chemotherapeutic agent temozolomide (TMZ) or with vehicle control. 13C 2D echo-planar spectroscopic imaging (EPSI) studies of hyperpolarized δ-[1-13C]gluconolactone metabolism were performed on rats bearing orthotopic glioblastoma tumors or tumor-free controls on a 3T spectrometer. Longitudinal 2D EPSI studies of hyperpolarized δ-[1-13C]gluconolactone metabolism and T2-weighted magnetic resonance imaging (MRI) were performed in rats bearing orthotopic U251 tumors following treatment with TMZ to examine the ability of hyperpolarized δ-[1-13C]gluconolactone to report on treatment response.ResultsPGLS knockdown downregulated NADPH and GSH, elevated oxidative stress and inhibited clonogenicity in all models. Conversely, PGLS expression and activity and steady-state NADPH and GSH were higher in tumor tissues from rats bearing orthotopic glioblastoma xenografts relative to contralateral brain and tumor-free brain. Importantly, [1-13C]6PG production from hyperpolarized δ-[1-13C]gluconolactone was observed in live glioblastoma cells and was significantly reduced by treatment with TMZ. Furthermore, hyperpolarized δ-[1-13C]gluconolactone metabolism to [1-13C]6PG could differentiate tumor from contralateral normal brain in vivo. Notably, TMZ significantly reduced 6PG production from hyperpolarized δ-[1-13C]gluconolactone at an early timepoint prior to volumetric alterations as assessed by anatomical imaging.ConclusionsCollectively, we have, for the first time, identified a role for PGLS activity in glioblastoma proliferation and validated the utility of probing PGLS activity using hyperpolarized δ-[1-13C]gluconolactone for non-invasive in vivo imaging of glioblastomas and their response to therapy.
- Published
- 2021
56. TAMI-08. A TALE OF TWO TELOMERE MAINTENANCE MECHANISMS: TERT EXPRESSION AND THE ALT PATHWAY INDUCE UNIQUE MRS-DETECTABLE METABOLIC REPROGRAMMING IN LOW-GRADE GLIOMAS
- Author
-
Hema Artee Luchman, Anne Marie Gillespie, Georgios Batsios, Sabrina M. Ronen, Joseph F. Costello, Russell O. Pieper, and Pavithra Viswanath
- Subjects
Cancer Research ,Oncology ,Metabolic reprogramming ,Cancer research ,Tumor Microenvironment/Angiogenesis/Metabolism/Invasion ,Neurology (clinical) ,Biology ,Telomere - Abstract
Telomeres are nucleoprotein structures at chromosomal ends that shorten with cell division and constitute a natural barrier to proliferation. In order to proliferate indefinitely, all tumors require a telomere maintenance mechanism (TMM). Telomerase reverse transcriptase (TERT) expression is the TMM in most tumors, including low-grade oligodendrogliomas (LGOGs). In contrast, low-grade astrocytomas (LGAs) use the alternative lengthening of telomeres (ALT) pathway as their TMM. As molecular hallmarks of tumor proliferation, TMMs are attractive tumor biomarkers and therapeutic targets. Non-invasive imaging of TMM status will, therefore, allow assessment of tumor proliferation and treatment response. However, translational methods of imaging TMM status are lacking. Here, we show that TERT expression and the ALT pathway are associated with unique magnetic resonance spectroscopy (MRS)-detectable metabolic reprogramming in LGOGs and LGAs respectively. In genetically-engineered and patient-derived LGOG models, TERT expression is linked to elevated 1H-MRS-detectable NAD(P)/H, glutathione, aspartate and AXP. In contrast, the ALT pathway in LGAs is associated with higher α-ketoglutarate, glutamate, alanine and AXP. Importantly, elevated flux of hyperpolarized [1-13C]-alanine to pyruvate, which depends on α-ketoglutarate, is a non-invasive in vivo imaging biomarker of the ALT pathway in LGAs while elevated flux of hyperpolarized [1-13C]-alanine to lactate, which depends on NADH, is an imaging biomarker of TERT expression in LGOGs. Mechanistically, the ALT pathway in LGAs is linked to higher glutaminase (GLS), a key enzyme for α-ketoglutarate biosynthesis while TERT expression in LGOGs is associated with elevated nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme for NADH biosynthesis. Notably, TERT expression and the ALT pathway are linked to MRS-detectable metabolic reprogramming in LGOG and LGA patient biopsies, emphasizing the clinical validity of our observations. Collectively, we have identified unique metabolic signatures of TMM status that integrate critical oncogenic information with noninvasive imaging modalities that can improve diagnosis and treatment response monitoring for LGOG and LGA patients.
- Published
- 2020
57. Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment
- Author
-
Chloé Najac, Elavarasan Subramani, Georgios Batsios, Russell O. Pieper, Joseph F. Costello, Marina Radoul, Donghyun Hong, Pavithra Viswanath, Anne Marie Gillespie, Abigail R. Molloy, Romelyn Delos Santos, and Sabrina M. Ronen
- Subjects
0301 basic medicine ,Cancer Research ,Magnetic Resonance Spectroscopy ,Glutamine ,Nude ,Protein Engineering ,Mice ,Random Allocation ,0302 clinical medicine ,Pyruvic Acid ,Cancer ,Carbon Isotopes ,Tumor ,Chemistry ,Brain Neoplasms ,Glutamate receptor ,Glioma ,Alkylating ,Isocitrate Dehydrogenase ,Isocitrate dehydrogenase ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Biomedical Imaging ,Ketoglutaric Acids ,Female ,medicine.drug ,IDH1 ,Oncology and Carcinogenesis ,Glutamic Acid ,Mice, Nude ,Antineoplastic Agents ,Article ,03 medical and health sciences ,Rare Diseases ,In vivo ,medicine ,Biomarkers, Tumor ,Temozolomide ,Animals ,Humans ,Oncology & Carcinogenesis ,Antineoplastic Agents, Alkylating ,Prevention ,Neurosciences ,medicine.disease ,Brain Disorders ,Brain Cancer ,Citric acid cycle ,030104 developmental biology ,Glucose ,Mutation ,Cancer research ,Biomarkers - Abstract
Although lower grade gliomas are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene and are less aggressive than primary glioblastoma, they nonetheless generally recur. IDH1-mutant patients are increasingly being treated with temozolomide, but early detection of response remains a challenge and there is a need for complementary imaging methods to assess response to therapy prior to tumor shrinkage. The goal of this study was to determine the value of magnetic resonance spectroscopy (MRS)–based metabolic changes for detection of response to temozolomide in both genetically engineered and patient-derived mutant IDH1 models. Using 1H MRS in combination with chemometrics identified several metabolic alterations in temozolomide-treated cells, including a significant increase in steady-state glutamate levels. This was confirmed in vivo, where the observed 1H MRS increase in glutamate/glutamine occurred prior to tumor shrinkage. Cells labeled with [1–13C]glucose and [3–13C]glutamine, the principal sources of cellular glutamate, showed that flux to glutamate both from glucose via the tricarboxylic acid cycle and from glutamine were increased following temozolomide treatment. In line with these results, hyperpolarized [5–13C]glutamate produced from [2–13C]pyruvate and hyperpolarized [1–13C]glutamate produced from [1–13C]α-ketoglutarate were significantly higher in temozolomide-treated cells compared with controls. Collectively, our findings identify 1H MRS-detectable elevation of glutamate and hyperpolarized 13C MRS-detectable glutamate production from either pyruvate or α-ketoglutarate as potential translatable metabolic biomarkers of response to temozolomide treatment in mutant IDH1 glioma. Significance: These findings show that glutamate can be used as a noninvasive, imageable metabolic marker for early assessment of tumor response to temozolomide, with the potential to improve treatment strategies for mutant IDH1 patients.
- Published
- 2020
58. Imaging 6-Phosphogluconolactonase Activity in Brain Tumors
- Author
-
Georgios, Batsios, Céline, Taglang, Peng, Cao, Anne Marie, Gillespie, Chloé, Najac, Elavarasan, Subramani, David M, Wilson, Robert R, Flavell, Peder E Z, Larson, Sabrina M, Ronen, and Pavithra, Viswanath
- Subjects
pentose phosphate pathway (PPP) ,dynamic nuclear polarization (DNP) ,Oncology ,glioblastoma ,brain tumors ,hyperpolarized 13C MRS ,6-phosphogluconolactonase (PGLS) ,metabolic therapy ,Original Research ,magnetic resonance spectroscopy/imaging (MRS/I) - Abstract
Introduction The pentose phosphate pathway (PPP) is essential for NADPH generation and redox homeostasis in cancer, including glioblastomas. However, the precise contribution to redox and tumor proliferation of the second PPP enzyme 6-phosphogluconolactonase (PGLS), which converts 6-phospho-δ-gluconolactone to 6-phosphogluconate (6PG), remains unclear. Furthermore, non-invasive methods of assessing PGLS activity are lacking. The goal of this study was to examine the role of PGLS in glioblastomas and assess the utility of probing PGLS activity using hyperpolarized δ-[1-13C]gluconolactone for non-invasive imaging. Methods To interrogate the function of PGLS in redox, PGLS expression was silenced in U87, U251 and GS2 glioblastoma cells by RNA interference and levels of NADPH and reduced glutathione (GSH) measured. Clonogenicity assays were used to assess the effect of PGLS silencing on glioblastoma proliferation. Hyperpolarized δ-[1-13C]gluconolactone metabolism to 6PG was assessed in live cells treated with the chemotherapeutic agent temozolomide (TMZ) or with vehicle control. 13C 2D echo-planar spectroscopic imaging (EPSI) studies of hyperpolarized δ-[1-13C]gluconolactone metabolism were performed on rats bearing orthotopic glioblastoma tumors or tumor-free controls on a 3T spectrometer. Longitudinal 2D EPSI studies of hyperpolarized δ-[1-13C]gluconolactone metabolism and T2-weighted magnetic resonance imaging (MRI) were performed in rats bearing orthotopic U251 tumors following treatment with TMZ to examine the ability of hyperpolarized δ-[1-13C]gluconolactone to report on treatment response. Results PGLS knockdown downregulated NADPH and GSH, elevated oxidative stress and inhibited clonogenicity in all models. Conversely, PGLS expression and activity and steady-state NADPH and GSH were higher in tumor tissues from rats bearing orthotopic glioblastoma xenografts relative to contralateral brain and tumor-free brain. Importantly, [1-13C]6PG production from hyperpolarized δ-[1-13C]gluconolactone was observed in live glioblastoma cells and was significantly reduced by treatment with TMZ. Furthermore, hyperpolarized δ-[1-13C]gluconolactone metabolism to [1-13C]6PG could differentiate tumor from contralateral normal brain in vivo. Notably, TMZ significantly reduced 6PG production from hyperpolarized δ-[1-13C]gluconolactone at an early timepoint prior to volumetric alterations as assessed by anatomical imaging. Conclusions Collectively, we have, for the first time, identified a role for PGLS activity in glioblastoma proliferation and validated the utility of probing PGLS activity using hyperpolarized δ-[1-13C]gluconolactone for non-invasive in vivo imaging of glioblastomas and their response to therapy.
- Published
- 2020
59. In vivo detection of γ-glutamyl-transferase up-regulation in glioma using hyperpolarized γ-glutamyl-[1-13C]glycine
- Author
-
Peder E. Z. Larson, Hikari A. I. Yoshihara, Shinsuke Sando, Chloé Najac, Anne Marie Gillespie, Pavithra Viswanath, Elavarasan Subramani, Yutaro Saito, Georgios Batsios, Sabrina M. Ronen, and Peng Cao
- Subjects
0301 basic medicine ,Male ,lcsh:Medicine ,medicine.disease_cause ,chemistry.chemical_compound ,0302 clinical medicine ,lcsh:Science ,Cancer ,Carbon Isotopes ,Multidisciplinary ,Tumor ,Chemistry ,Brain ,gamma-Glutamyltransferase ,Dipeptides ,Magnetic Resonance Imaging ,Up-Regulation ,Molecular Imaging ,Biomedical Imaging ,digestive system ,Cell Line ,03 medical and health sciences ,Rare Diseases ,Downregulation and upregulation ,In vivo ,Glioma ,medicine ,Animals ,Humans ,Neoplastic ,lcsh:R ,Neurosciences ,Glutathione ,medicine.disease ,Molecular biology ,Xenograft Model Antitumor Assays ,digestive system diseases ,Brain Disorders ,Rats ,Brain Cancer ,030104 developmental biology ,Gene Expression Regulation ,Cell culture ,Molecular Probes ,Glycine ,Feasibility Studies ,lcsh:Q ,Glioblastoma ,030217 neurology & neurosurgery ,Homeostasis ,Oxidative stress - Abstract
Glutathione (GSH) is often upregulated in cancer, where it serves to mitigate oxidative stress. γ-glutamyl-transferase (GGT) is a key enzyme in GSH homeostasis, and compared to normal brain its expression is elevated in tumors, including in primary glioblastoma. GGT is therefore an attractive imaging target for detection of glioblastoma. The goal of our study was to assess the value of hyperpolarized (HP) γ-glutamyl-[1-13C]glycine for non-invasive imaging of glioblastoma. Nude rats bearing orthotopic U87 glioblastoma and healthy controls were investigated. Imaging was performed by injecting HP γ-glutamyl-[1-13C]glycine and acquiring dynamic 13C data on a preclinical 3T MR scanner. The signal-to-noise (SNR) ratios of γ-glutamyl-[1-13C]glycine and its product [1-13C]glycine were evaluated. Comparison of control and tumor-bearing rats showed no difference in γ-glutamyl-[1-13C]glycine SNR, pointing to similar delivery to tumor and normal brain. In contrast, [1-13C]glycine SNR was significantly higher in tumor-bearing rats compared to controls, and in tumor regions compared to normal-appearing brain. Importantly, higher [1-13C]glycine was associated with higher GGT expression and higher GSH levels in tumor tissue compared to normal brain. Collectively, this study demonstrates, to our knowledge for the first time, the feasibility of using HP γ-glutamyl-[1-13C]glycine to monitor GGT expression in the brain and thus to detect glioblastoma.
- Published
- 2020
60. Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma
- Author
-
Matthew R. Grimmer, Joanna J. Phillips, Sabrina M. Ronen, Joydeep Mukherjee, Chloé Najac, Tali Mazor, Lindsey E Jones, Russell O. Pieper, Susan M. Chang, Andrew McKinney, Tracy T. Chow, Joseph F. Costello, and Stephanie Hilz
- Subjects
0301 basic medicine ,intratumoral heterogeneity and evolution ,IDH1-mutant glioma ,Somatic hypermutation ,Biology ,medicine.disease_cause ,Germline ,patient-derived cells ,03 medical and health sciences ,0302 clinical medicine ,Rare Diseases ,Glioma ,medicine ,Genetics ,AcademicSubjects/MED00300 ,Cancer ,Mutation ,hypermutation ,Human Genome ,Neurosciences ,Astrocytoma ,hemic and immune systems ,intracranial xenograft ,medicine.disease ,Phenotype ,Brain Disorders ,Brain Cancer ,030104 developmental biology ,030220 oncology & carcinogenesis ,Basic and Translational Investigations ,Cancer research ,AcademicSubjects/MED00310 ,Oligodendroglioma ,Carcinogenesis - Abstract
Background IDH-mutant lower-grade gliomas (LGGs) evolve under the selective pressure of therapy, but well-characterized patient-derived cells (PDCs) modeling evolutionary stages are lacking. IDH-mutant LGGs may develop therapeutic resistance associated with chemotherapy-driven hypermutation and malignant progression. The aim of this study was to establish and characterize PDCs, single-cell-derived PDCs (scPDCs), and xenografts (PDX) of IDH1-mutant recurrences representing distinct stages of tumor evolution. Methods We derived and validated cell cultures from IDH1-mutant recurrences of astrocytoma and oligodendroglioma. We used exome sequencing and phylogenetic reconstruction to examine the evolutionary stage represented by PDCs, scPDCs, and PDX relative to corresponding spatiotemporal tumor tissue and germline DNA. PDCs were also characterized for growth and tumor immortality phenotypes, and PDX were examined histologically. Results The integrated astrocytoma phylogeny revealed 2 independent founder clonal expansions of hypermutated (HM) cells in tumor tissue that are faithfully represented by independent PDCs. The oligodendroglioma phylogeny showed more than 4000 temozolomide-associated mutations shared among tumor samples, PDCs, scPDCs, and PDX, suggesting a shared monoclonal origin. The PDCs from both subtypes exhibited hallmarks of tumorigenesis, retention of subtype-defining genomic features, production of 2-hydroxyglutarate, and subtype-specific telomere maintenance mechanisms that confer tumor cell immortality. The oligodendroglioma PDCs formed infiltrative intracranial tumors with characteristic histology. Conclusions These PDCs, scPDCs, and PDX are unique and versatile community resources that model the heterogeneous clonal origins and functions of recurrent IDH1-mutant LGGs. The integrated phylogenies advance our knowledge of the complex evolution and immense mutational load of IDH1-mutant HM glioma.
- Published
- 2020
61. C-13 Hyperpolarized MR Spectroscopy for Metabolic Imaging of Brain Tumors
- Author
-
Yan Li, Sabrina M. Ronen, and Pavithra Viswanath
- Subjects
In vivo magnetic resonance spectroscopy ,Noninvasive imaging ,Response to therapy ,business.industry ,Metabolic imaging ,Glioma ,Brain tumor ,Medicine ,business ,medicine.disease ,Neuroscience ,Patient management - Abstract
Our understanding of the molecular basis of glioma initiation and maintenance has increased tremendously in recent years. This information needs to be incorporated into clinical patient management in order to make personalized neuro-oncology a reality. One promising approach is metabolic imaging, which can translate metabolic information that reflects the molecular features of glioma into noninvasive imaging biomarkers that can impact diagnosis, treatment selection, and monitoring of response to therapy. A novel metabolic imaging modality is hyperpolarized 13C-magnetic resonance spectroscopy (MRS) which can be used to noninvasively quantify metabolic fluxes in real time in vivo. The aim of this review is to provide an understanding of the current state of the art in glioma imaging using hyperpolarized 13C-MRS. We will review the various hyperpolarized 13C-MRS studies in preclinical glioma models as well as studies in brain tumor patients that highlight the promise and the challenges associated with translation of this technology to the clinic.
- Published
- 2019
62. CBMT-02. UP-REGULATION OF Γ-GLUTAMYL-TRANSFERASE CAN BE USED TO IMAGE GLIOBLASTOMA USING HYPERPOLARIZED Γ-GLUTAMYL-[1-(13)C]GLYCINE MRS
- Author
-
Yutaro Saito, Shinsuke Sando, Anne Marie Gillespie, Peder E. Z. Larson, Peng Cao, Georgios Batsios, Pavithra Viswanath, Hikari A. I. Yoshihara, Sabrina M. Ronen, Chloé Najac, and Elavarasan Subramani
- Subjects
Cancer Research ,Oncology ,Biochemistry ,Downregulation and upregulation ,Chemistry ,Glycine ,medicine ,Neurology (clinical) ,medicine.disease ,γ glutamyl transferase ,Cell Biology and Metabolism ,Glioblastoma - Abstract
γ-glutamyl-transferase (GGT) is a key enzyme in the γ-glutamyl cycle, which regulates glutathione homeostasis. The enzyme is localized on the outer cell membrane and cleaves glutathione to glutamate and cysteinylglycine. As such, it facilitates uptake of the amino acids essential for intracellular synthesis of glutathione (GSH), which is the major thiol anti-oxidant. GGT is upregulated in glioblastoma, but remains low in normal brain. It is therefore an attractive molecular imaging target for specific detection of glioblastoma. The goal of our study was therefore to assess for the first time the value of hyperpolarized (HP) γ-glutamyl-[1-13C]glycine (γ-Glu-[1-13C]Gly) for imaging glioblastoma in orthotopic tumor-bearing rats. Athymic nude rats with U87 glioblastoma tumors or tumor-free controls were investigated. First, we confirmed that GGT expression was significantly higher in U87 tumors compared to normal rat brain tissue. GSH levels were also higher. Imaging studies were then performed by injecting HP γ-Glu-[1-13C]Gly and acquiring dynamic 13C MR spectra using a flyback spectral-spatial slab sequence on a preclinical Bruker 3T MR system. The dynamic data were analyzed by measuring the signal-to-noise (SNR) ratios of the substrate (γ-Glu-[1-13C]Gly) and the product ([1-13C]Glycine). Comparison of control and tumor-bearing rats showed no statistically significant difference in the SNR of the substrate. In contrast, the SNR of the product demonstrated a significantly higher level of HP [1-13C]Glycine in the tumor-bearing rats compared to controls. Consistent with the higher levels of HP [1-13C]Glycine, the [1-13C]Gly-to-γ-Glu-[1-13C]Glycine ratio was also significantly higher in tumor-bearing animals relative to controls (0.046±0.004 vs 0.021±0.008 respectively; p=0.03). Further studies are needed to assess the generality of our findings. Nonetheless, this study demonstrates for the first time the feasibility of using γ-Glu-[1-13C]Gly to monitor GGT activity and thus could serve as a new approach for monitoring the presence of tumor.
- Published
- 2019
63. EXTH-20. HYPERPOLARIZED [2-(13)C] PYRUVATE TO [5-(13)C] GLUTAMATE AS BIOMARKERS OF IDH1 MUTANT GLIOMA RESPONSE TO TEMOZOLOMIDE THERAPY
- Author
-
Sabrina M. Ronen, Russell O. Pieper, Anne Marie Gillespie, Pavithra Viswanath, Chloé Najac, Elavarasan Subramani, Marina Radoul, and Georgios Batsios
- Subjects
Cancer Research ,IDH1 ,Temozolomide ,Chemistry ,Mutant ,Glutamate receptor ,medicine.disease ,Glutamine ,Citric acid cycle ,Isocitrate dehydrogenase ,Oncology ,Glioma ,medicine ,Cancer research ,Experimental Therapeutics ,Neurology (clinical) ,medicine.drug - Abstract
Low-grade gliomas, driven by mutations in the cytosolic isocitrate dehydrogenase 1 (IDH1) gene, are less aggressive than primary glioblastoma, but nonetheless always recur and ultimately lead to patient death. The treatment of IDH1 mutant patients with Temozolomide (TMZ) improves survival, but there remains a need for complementary imaging methods to assess response to therapy at an early time point. The goal of this study was, therefore, to determine the value of magnetic resonance spectroscopy (MRS)-based metabolic imaging biomarkers for detection of response to treatment. To this end we investigated NHA and U87 cells expressing IDH1 R132H mutant gene (NHAIDHmut and U87IDHmut) and first used 1H MRS combined with chemometrics to examined the metabolic alterations that occurred following treatment with the IC50 value of TMZ. We observed a significant increase in 2-hydroxyglutarate (2-HG), glutamate, and glutamine, and metabolic pathway analysis showed tricarboxylic acid (TCA) cycle and pyruvate metabolism to be significantly altered pathways following TMZ treatment compared to DMSO control. To confirm changes in TCA cycle flux and to assess the metabolic pathways contributing to the increase in 2-HG and glutamate/glutamine, cells were then labelled with [1-13C] glucose and [3-13C] glutamine. Our data indicated that both glucose flux via the TCA to glutamate and 2HG, and the contribution of glutamine to glutamate and 2HG were increased following TMZ treatment. Finally, we used hyperpolarized 13C-MRS to dynamically probe the metabolism of hyperpolarized [2-13C] pyruvate and its conversion to hyperpolarized [5-13C] glutamate via the TCA cycle. Consistent with our previous findings, we observed that hyperpolarized [5-13C] glutamate synthesis was significantly higher in TMZ-treated cells compared to controls. Collectively, our findings identify 1H MRS-detectable elevation of 2-HG and glutamate/glutamine as well as hyperpolarized 13C-MRS-detectable [5-13C] glutamate production from [2-13C] pyruvate as potentially translatable metabolic biomarkers of response to TMZ therapy in mutant IDH1 glioma.
- Published
- 2019
64. 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas
- Author
-
Marina Radoul, Jose L. Izquierdo-Garcia, Russell O. Pieper, Joanna J. Phillips, Wei Qiang Ong, Bo Huang, Pavithra Viswanath, J. Gregory Cairncross, Hema Artee Luchman, and Sabrina M. Ronen
- Subjects
0301 basic medicine ,Cancer Research ,Biopsy ,Endoplasmic Reticulum ,Mice ,chemistry.chemical_compound ,Models ,2.1 Biological and endogenous factors ,Aetiology ,Phospholipids ,Cancer ,Tumor ,Glioma ,Magnetic Resonance Imaging ,Isocitrate Dehydrogenase ,Cell biology ,Gene Expression Regulation, Neoplastic ,Oncology ,lipids (amino acids, peptides, and proteins) ,Oncology and Carcinogenesis ,Models, Biological ,Article ,Cell Line ,Glutarates ,03 medical and health sciences ,Rare Diseases ,Downregulation and upregulation ,Cell Line, Tumor ,Autophagy ,medicine ,Animals ,Humans ,Gene Silencing ,Oncology & Carcinogenesis ,Phosphatidylethanolamine ,Neoplastic ,Endoplasmic reticulum ,Biological ,medicine.disease ,Brain Disorders ,Brain Cancer ,030104 developmental biology ,Gene Expression Regulation ,chemistry ,Cell culture ,Mutation ,Proteolysis ,Cancer cell ,Unfolded protein response ,Biomarkers - Abstract
Tumor metabolism is reprogrammed to meet the demands of proliferating cancer cells. In particular, cancer cells upregulate synthesis of the membrane phospholipids phosphatidylcholine (PtdCho) and phosphatidylethanolamine (PtdE) in order to allow for rapid membrane turnover. Nonetheless, we show here that, in mutant isocitrate dehydrogenase 1 (IDHmut) gliomas, which produce the oncometabolite 2-hydroxyglutarate (2-HG), PtdCho and PtdE biosynthesis is downregulated and results in lower levels of both phospholipids when compared with wild-type IDH1 cells. 2-HG inhibited collagen-4-prolyl hydroxylase activity, leading to accumulation of misfolded procollagen-IV in the endoplasmic reticulum (ER) of both genetically engineered and patient-derived IDHmut glioma models. The resulting ER stress triggered increased expression of FAM134b, which mediated autophagic degradation of the ER (ER-phagy) and a reduction in the ER area. Because the ER is the site of phospholipid synthesis, ER-phagy led to reduced PtdCho and PtdE biosynthesis. Inhibition of ER-phagy via pharmacological or molecular approaches restored phospholipid biosynthesis in IDHmut glioma cells, triggered apoptotic cell death, inhibited tumor growth, and prolonged the survival of orthotopic IDHmut glioma-bearing mice, pointing to a potential therapeutic opportunity. Glioma patient biopsies also exhibited increased ER-phagy and downregulation of PtdCho and PtdE levels in IDHmut samples compared with wild-type, clinically validating our observations. Collectively, this study provides detailed and clinically relevant insights into the functional link between oncometabolite-driven ER-phagy and phospholipid biosynthesis in IDHmut gliomas. Significance: Downregulation of phospholipid biosynthesis via ER-phagy is essential for proliferation and clonogenicity of mutant IDH1 gliomas, a finding with immediate therapeutic implications. Cancer Res; 78(9); 2290–304. ©2018 AACR.
- Published
- 2018
65. Late-stage deuteration of13C-enriched substrates forT1prolongation in hyperpolarized13C MRI
- Author
-
Chloé Najac, Joseph E. Blecha, David E. Korenchan, Robert R. Flavell, Justin Yu, Sabrina M. Ronen, Robert Bok, Renuka Sriram, Cornelius von Morze, Sukumar Subramaniam, John Kurhanewicz, Daniel B. Vigneron, David M. Wilson, Céline Taglang, Sinan Wang, and Henry F. VanBrocklin
- Subjects
Alanine ,biology ,Stereochemistry ,Chemistry ,Metals and Alloys ,Hyperpolarized 13c ,General Chemistry ,010402 general chemistry ,01 natural sciences ,Catalysis ,In vitro ,Enzyme assay ,030218 nuclear medicine & medical imaging ,0104 chemical sciences ,Surfaces, Coatings and Films ,Electronic, Optical and Magnetic Materials ,Serine ,03 medical and health sciences ,0302 clinical medicine ,Deuterium ,Valine ,Kinetic isotope effect ,Materials Chemistry ,Ceramics and Composites ,biology.protein - Abstract
A robust and selective late-stage deuteration methodology was applied to 13C-enriched amino and alpha hydroxy acids to increase spin–lattice relaxation constant T1 for hyperpolarized 13C magnetic resonance imaging. For the five substrates with 13C-labeling on the C1-position ([1-13C]alanine, [1-13C]serine, [1-13C]lactate, [1-13C]glycine, and [1-13C]valine), significant increase of their T1 was observed at 3 T with deuterium labeling (+26%, 22%, +16%, +25% and +29%, respectively). Remarkably, in the case of [2-13C]alanine, [2-13C]serine and [2-13C]lactate, deuterium labeling led to a greater than four fold increase in T1. [1-13C,2-2H]alanine, produced using this method, was applied to in vitro enzyme assays with alanine aminotransferase, demonstrating a kinetic isotope effect.
- Published
- 2018
66. BIOM-14. METABOLIC BIOMARKERS OF TERT-TARGETED THERAPY FOR HUMAN GLIOBLASTOMA DETECTED BY MAGNETIC RESONANCE SPECTROSCOPY
- Author
-
Sabrina M. Ronen, Joseph F. Costello, Pavithra Viswanath, Russell O. Pieper, Noriaki Minami, Nicholas Stevers, Anne Marie Gillespie, Donghyun Hong, and Georgios Batsios
- Subjects
Cancer Research ,Mutation ,Metabolic biomarkers ,Chemistry ,medicine.medical_treatment ,Nuclear magnetic resonance spectroscopy ,26th Annual Meeting & Education Day of the Society for Neuro-Oncology ,Precision medicine ,medicine.disease_cause ,medicine.disease ,Targeted therapy ,Oncology ,medicine ,Cancer research ,Glycolysis ,Neurology (clinical) ,Transcription factor ,Glioblastoma - Abstract
BACKGROUND TERT promoter mutations that result in TERT expression are observed in over 80% of GBM. Moreover, the upstream transcription factor GABPB1 was recently identified as an ideal therapeutic target for tumors with TERT promoter mutations. In that context, non-invasive reliable biomarkers that can help detect TERT expression are needed. The aim of this research was to assess the value of MRS-detectable metabolic changes as biomarkers of TERT expression and TERT-targeted therapy in GBM. METHODS Genetically engineered GBM cells (NHARas/TERT) treated with TERT siRNA were compared to siCtrl-treated cells, and stable TERT and GABPB1 knock down GBM cells (U251, GBM1) were compared to shCtrl. 1H-MRS and 13C-MRS metabolic data was acquired from cell extracts using a Bruker 500MHz scanner. Hyperpolarized MRS studies of live cells used a HyperSense DNP polarizer and data was acquired using a Varian 500MHz scanner. Spectra were analyzed using Mnova and Matlab software. Multivariate data analysis was performed using SIMCA software. RESULTS Unbiased PCA analysis of 1H-MRS metabolic data showed separation of TERT or GABPB1 knock down and control cells. VIP predictive scores revealed that lactate and GSH were the top altered metabolites with a significant drop observed in both metabolites in every model following TERT silencing. Consistent with the reduction in GSH, spectrophotometric assays showed a significant drop in NADPH and NADH. 2-13C glucose flux analysis revealed that both glycolysis and PPP-related metabolites were reduced in TERT knock down cells. Hyperpolarized [1-13C]-pyruvate flux to lactate was also reduced, confirming that the glycolytic pathway was altered following TERT knock down. CONCLUSION 1H MRS-detectable lactate and GSH, combined with hyperpolarized 13C MRS-detectable metabolic fluxes, could serve as metabolic biomarkers of TERT-targeted therapy for human GBM with TERT promoter mutations. These biomarkers could be translated to the clinical, improve the monitoring of GBM patients and advance precision medicine.
- Published
- 2021
67. EXTH-46. MRS BASED BIOMARKERS OF IDH1 MUTANT GLIOMA RESPONSE TO THE IDH INHIBITOR BAY-1436032
- Author
-
Céline Taglang, Noriaki Minami, Donghyun Hong, Sabrina M. Ronen, Pavithra Viswanath, Joseph F. Costello, Anne Marie Gillespie, Georgios Batsios, and Russell O. Pieper
- Subjects
Cancer Research ,IDH1 ,Mutant ,Cancer ,Biology ,medicine.disease ,Animal model ,Isocitrate dehydrogenase ,Oncology ,Glioma ,medicine ,Cancer research ,Inhibitory concentration 50 ,Neurology (clinical) ,Bay - Abstract
Gliomas are the most prevalent type of brain tumor in the central nervous system. Mutations in the cytosolic enzyme isocitrate dehydrogenase 1 (IDH1) are a common feature of primary low-grade gliomas, catalyzing the conversion of α-ketoglutarate (αKG) to the oncometabolite 2-hydroxyglutarate (2HG), and mutant IDH1 is a therapeutic target for these tumors. Several mutant IDH inhibitors are currently in clinical trials, nonetheless, complementary non-invasive early biomarkers to assess drug delivery and potential therapeutic response are still needed. The goal of this study was therefore to determine the potential of 1H and hyperpolarized 13C magnetic resonance spectroscopy (MRS)-based biomarkers as indicators of mutant IDH1 low-grade glioma response to treatment with the clinically-relevant IDH1 inhibitor BAY-1436032 in cells and animal models. Immortalized human astrocytes engineered to express mutant IDH1 were treated with 500nM (IC50 value) of BAY-1436032 and BT257 tumors implanted in rats were treated with 150mg/kg of BAY-1436032. To assess steady-state metabolite levels, 1H MRS spectra were acquired on a 500 MHz MRS cancer for cells and a 3 T scanner for animal studies. To assess metabolic fluxes, we used hyperpolarized 13C MRS and probed the fate of hyperpolarized [1-13C]αKG. 1H MRS showed a significant decrease in 2HG as well as a significant increase in glutamate (Glu) and phosphocholine (PCh) following BAY-1436032 treatment in both cell and animal models compared to controls. Furthermore, hyperpolarized 13C MRS showed that hyperpolarized 2HG production from hyperpolarized [1-13C]αKG was decreased and hyperpolarized glutamate production from hyperpolarized [1-13C]αKG was increased in the BAY-1436032 treated groups compared to controls. These findings are consistent with our previous study, which investigated the MRS-detectable consequences of two other mutant IDH inhibitors: AG120 and AG881. Collectively, our work identifies translatable MRS-based metabolic biomarkers of mutant IDH1 inhibition.
- Published
- 2021
68. BIMG-05. TO BE OR NOT TO BE GLYCOLYTIC: DEUTERATED GLUCOSE-BASED ASSESSMENT OF THE WARBURG EFFECT ALLOWS NON-INVASIVE IMAGING OF TUMOR BURDEN AND TREATMENT RESPONSE IN MUTANT IDH GLIOMAS IN VIVO
- Author
-
Georgios Batsios, Hema Artee Luchman, Sabrina M. Ronen, Meryssa Tran, Anne Marie Gillepsie, Pavithra Viswanath, Russell O. Pieper, and Céline Taglang
- Subjects
Chemistry ,Glucose uptake ,Mutant ,medicine.disease ,Warburg effect ,Supplement Abstracts ,chemistry.chemical_compound ,Isocitrate dehydrogenase ,In vivo ,Glioma ,Lactate dehydrogenase ,Cancer research ,medicine ,AcademicSubjects/MED00300 ,Metabolic Biomarkers and Imaging ,AcademicSubjects/MED00310 ,Glycolysis - Abstract
The Warburg effect, characterized by elevated glucose uptake and flux to lactate, is a metabolic hallmark of cancer. Recent studies have identified deuterium 2H-magnetic resonance spectroscopy (MRS) using 6,6’-2H-glucose as a novel method of imaging the Warburg effect in high-grade primary glioblastomas (GBMs). However, its utility for imaging low-grade gliomas has not been tested. The goal of this study was to determine whether 6,6’-2H-glucose can be used for imaging tumor burden and treatment response in mutant isocitrate dehydrogenase (IDHmut) low-grade gliomas in vivo. We examined mice bearing orthotopic tumors of the patient-derived BT257 astrocytoma model. 1H-MRS, providing a readout of steady-state metabolite levels, confirmed the presence of 2-hydroxyglutarate, the product of IDHmut, in BT257 tumor tissue but not normal brain. Previous studies comparing IDHmut gliomas with GBMs suggest that IDHmut gliomas undergo lactate dehydrogenase silencing, potentially leading to a non-glycolytic phenotype. Nevertheless, our results indicated that, compared to normal brain, glucose uptake and concomitant flux to lactate were significantly higher in BT257 tumor tissue. Importantly, 6,6’-2H-glucose metabolism to lactate was observed in BT257 tumor-bearing mice, but not tumor-free mice. Furthermore, imaging studies confirmed spatial localization of lactate production to the tumor vs. contralateral normal brain. We then examined the ability of 6,6’-2H-glucose to assess treatment response. Poly-(adenosine 5′-diphosphate-ribose) polymerase inhibitors (PARPi) inhibit IDHmut glioma growth and are in clinical trials for IDHmut glioma patients. Treatment with the PARPi niraparib reduced 6,6’-2H-glucose flux to lactate in BT257 tumor-bearing mice. Importantly, this reduction was observed at early time-points when no difference in tumor volume could be detected using anatomical imaging, pointing to the ability of 6,6’-2H-glucose to assess pseudoprogression. Collectively, our results suggest that IDHmut gliomas display a glycolytic phenotype amenable to non-invasive 2H-MRS-based imaging of tumor burden and treatment response.
- Published
- 2021
69. BIOM-19. METABOLIC ALTERATION INDUCED BY SELECTIVE KNOCK DOWN OF GABPB1L IN U251 CELLS
- Author
-
Pavithra Viswanath, Elavarasan Subramani, Anne Marie Gillespie, Georgios Batsios, Donghyun Hong, Noriaki Minami, Vinay Ayyappan, Nick Stevers, Joseph F. Costello, Marina Radoul, Sabrina M. Ronen, and Abigail R. Molloy
- Subjects
Cancer Research ,medicine.diagnostic_test ,Magnetic resonance imaging ,Nuclear magnetic resonance spectroscopy ,Glutathione ,Molecular biology ,Glutamine ,chemistry.chemical_compound ,Oncology ,chemistry ,Plasmid Vector ,Metabolic disturbance ,Mutation (genetic algorithm) ,medicine ,CRISPR ,Neurology (clinical) ,Biomarkers - Abstract
BACKGROUND TERT promoter mutations that result in TERT expression are observed in over 80% of GBM and upstream inhibition of TERT expression by targeting GABPB1L is currently under investigation. In that context, non-invasive reliable biomarkers that can help detect TERT expression are needed. The aim of this research was to assess the value of magnetic resonance spectroscopy (MRS)-detectable metabolic changes as biomarkers of TERT expression in GBM. METHODS GABPB1L knock down clones (GABPB1LKD) were established by introducing Crispr Cas9 plasmid vector targeting GABPB1L into U251 cells. Two representative clones with different knock down efficiency were chosen and compared to control cells. Tumor forming capacity was evaluated by colony formation assay and magnetic resonance imaging of orthotopically implanted tumors in mice. Cells were extracted using the dual phase extraction method and 1H-MRS data of cell extracts acquired using a Bruker 500 scanner. The data was analyzed using Mnova software. Multivariate analysis was performed using the SIMCA software. RESULTS TERT expression was significantly reduced in GABPB1LKD compared to control cells depending on the GABPB1L knock down efficiency. Colony forming capacity was impaired in GABPB1LKD compared to control cells. In vivo MRI data showed significantly smaller tumor volumes in GABPB1LKD compared to control. Unbiased PCA analysis of 1H-MRS data showed separation of GABPB1LKD and control extracts and VIP scores derived from the OPLS-DA analysis, demonstrated that the common metabolites leading to separation of GABPB1LKD and control cells were aspartate, glutathione, glycerophosphocholine, glutamine, NAD(P)+, AXP. This data was confirmed by univariate analysis that revealed that aspartate, glutathione, glutamine, NAD(P)+, AXP level was significantly reduced in GABPB1LKD. CONCLUSIONS GABPB1L knock down cells that show reduced TERT expression demonstrate MRS-detectable metabolic changes. These could be translated into clinical applications, improve the monitoring of GBM patients and advance precision medicine.
- Published
- 2020
70. In vivo detection of γ-glutamyl-transferase up-regulation in glioma using hyperpolarized γ-glutamyl-[1
- Author
-
Georgios, Batsios, Chloé, Najac, Peng, Cao, Pavithra, Viswanath, Elavarasan, Subramani, Yutaro, Saito, Anne Marie, Gillespie, Hikari A I, Yoshihara, Peder, Larson, Shinsuke, Sando, and Sabrina M, Ronen
- Subjects
Male ,Carbon Isotopes ,Brain ,Dipeptides ,gamma-Glutamyltransferase ,digestive system ,Magnetic Resonance Imaging ,Xenograft Model Antitumor Assays ,Cancer metabolism ,digestive system diseases ,Article ,Molecular Imaging ,Rats ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Tumour biomarkers ,Cell Line, Tumor ,Molecular Probes ,Animals ,Feasibility Studies ,Humans ,Cancer imaging ,Glioblastoma ,Cancer - Abstract
Glutathione (GSH) is often upregulated in cancer, where it serves to mitigate oxidative stress. γ-glutamyl-transferase (GGT) is a key enzyme in GSH homeostasis, and compared to normal brain its expression is elevated in tumors, including in primary glioblastoma. GGT is therefore an attractive imaging target for detection of glioblastoma. The goal of our study was to assess the value of hyperpolarized (HP) γ-glutamyl-[1-13C]glycine for non-invasive imaging of glioblastoma. Nude rats bearing orthotopic U87 glioblastoma and healthy controls were investigated. Imaging was performed by injecting HP γ-glutamyl-[1-13C]glycine and acquiring dynamic 13C data on a preclinical 3T MR scanner. The signal-to-noise (SNR) ratios of γ-glutamyl-[1-13C]glycine and its product [1-13C]glycine were evaluated. Comparison of control and tumor-bearing rats showed no difference in γ-glutamyl-[1-13C]glycine SNR, pointing to similar delivery to tumor and normal brain. In contrast, [1-13C]glycine SNR was significantly higher in tumor-bearing rats compared to controls, and in tumor regions compared to normal-appearing brain. Importantly, higher [1-13C]glycine was associated with higher GGT expression and higher GSH levels in tumor tissue compared to normal brain. Collectively, this study demonstrates, to our knowledge for the first time, the feasibility of using HP γ-glutamyl-[1-13C]glycine to monitor GGT expression in the brain and thus to detect glioblastoma.
- Published
- 2019
71. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
- Author
-
Chloé Najac, Elavarasan Subramani, Anne Marie Gillespie, Abigail R. Molloy, Romelyn Delos Santos, Pavithra Viswanath, Georgios Batsios, Sabrina M. Ronen, and Russell O. Pieper
- Subjects
0301 basic medicine ,Glutamine ,lcsh:Medicine ,Cell Cycle Proteins ,Kaplan-Meier Estimate ,medicine.disease_cause ,Mice ,Phosphatidylinositol 3-Kinases ,0302 clinical medicine ,Phosphorylation ,lcsh:Science ,Cell Line, Transformed ,Cancer ,Sulfonamides ,Multidisciplinary ,Chemistry ,Brain Neoplasms ,TOR Serine-Threonine Kinases ,Adaptor Proteins ,Glioma ,Cancer metabolism ,Isocitrate Dehydrogenase ,Neoplasm Proteins ,Isocitrate dehydrogenase ,Biomarker (medicine) ,Signal transduction ,Signal Transduction ,IDH1 ,Nuclear Magnetic Resonance ,Article ,Cell Line ,Glutarates ,03 medical and health sciences ,Targeted therapies ,Rare Diseases ,In vivo ,Quinoxalines ,medicine ,Animals ,Humans ,Nuclear Magnetic Resonance, Biomolecular ,PI3K/AKT/mTOR pathway ,Protein Processing ,Adaptor Proteins, Signal Transducing ,Ribosomal Protein S6 Kinases ,lcsh:R ,Signal Transducing ,Post-Translational ,Neurosciences ,medicine.disease ,Xenograft Model Antitumor Assays ,Brain Disorders ,CNS cancer ,Brain Cancer ,030104 developmental biology ,Glucose ,Orphan Drug ,Transformed ,Astrocytes ,Cancer research ,lcsh:Q ,Cancer imaging ,Carcinogenesis ,Protein Processing, Post-Translational ,030217 neurology & neurosurgery ,Biomolecular - Abstract
70–90% of low-grade gliomas and secondary glioblastomas are characterized by mutations in isocitrate dehydrogenase 1 (IDHmut). IDHmut produces the oncometabolite 2-hydroxyglutarate (2HG), which drives tumorigenesis in these tumors. The phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway represents an attractive therapeutic target for IDHmut gliomas, but noninvasive indicators of drug target modulation are lacking. The goal of this study was therefore to identify magnetic resonance spectroscopy (MRS)-detectable metabolic biomarkers associated with IDHmut glioma response to the dual PI3K/(mTOR) inhibitor XL765. 1H-MRS of two cell lines genetically modified to express IDHmut showed that XL765 induced a significant reduction in several intracellular metabolites including 2HG. Importantly, examination of an orthotopic IDHmut tumor model showed that enhanced animal survival following XL765 treatment was associated with a significant in vivo1H-MRS detectable reduction in 2HG but not with significant inhibition in tumor growth. Further validation is required, but our results indicate that 2HG could serve as a potential noninvasive MRS-detectable metabolic biomarker of IDHmut glioma response to PI3K/mTOR inhibition.
- Published
- 2019
72. First hyperpolarized [2
- Author
-
Brian T, Chung, Hsin-Yu, Chen, Jeremy, Gordon, Daniele, Mammoli, Renuka, Sriram, Adam W, Autry, Lydia M, Le Page, Myriam M, Chaumeil, Peter, Shin, James, Slater, Chou T, Tan, Chris, Suszczynski, Susan, Chang, Yan, Li, Robert A, Bok, Sabrina M, Ronen, Peder E Z, Larson, John, Kurhanewicz, and Daniel B, Vigneron
- Subjects
Brain Chemistry ,Carbon Isotopes ,Magnetic Resonance Spectroscopy ,Brain ,Glutamic Acid ,Sterilization ,Signal-To-Noise Ratio ,Magnetic Resonance Imaging ,Healthy Volunteers ,Article ,Area Under Curve ,Pyruvic Acid ,Animals ,Feasibility Studies ,Humans ,Lactic Acid ,Energy Metabolism - Abstract
We developed methods for the preparation of hyperpolarized (HP) sterile [2-(13)C]pyruvate to test its feasibility in first-ever human NMR studies following FDA-IND & IRB approval. Spectral results using this MR stable-isotope imaging approach demonstrated the feasibility of investigating human cerebral energy metabolism by measuring the dynamic conversion of HP [2-(13)C]pyruvate to [2-(13)C]lactate and [5-(13)C]glutamate in the brain of four healthy volunteers. Metabolite kinetics, signal-to-noise (SNR) and area-undercurve (AUC) ratios, and calculated [2-(13)C]pyruvate to [2-(13)C]lactate conversion rates (k(PL)) were measured and showed similar but not identical inter-subject values. The k(PL) measurements were equivalent with prior human HP [1-(13)C]pyruvate measurements.
- Published
- 2019
73. In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma
- Author
-
Chloé Najac, Sabrina M. Ronen, Anne Marie Gillespie, Lydia M. Le Page, Georgios Batsios, Elavarasan Subramani, Pavithra Viswanath, and Marina Radoul
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Magnetic Resonance Spectroscopy ,lcsh:Medicine ,Dehydrogenase ,Blood–brain barrier ,Acetoacetates ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Rare Diseases ,In vivo ,Glioma ,Internal medicine ,medicine ,Animals ,lcsh:Science ,Cancer ,chemistry.chemical_classification ,Reactive oxygen species ,Multidisciplinary ,Chemistry ,lcsh:R ,Neurosciences ,Brain ,medicine.disease ,3. Good health ,Mitochondria ,Brain Disorders ,Brain Cancer ,030104 developmental biology ,Endocrinology ,medicine.anatomical_structure ,Spectrophotometry ,Cancer cell ,Neurological ,Ketone bodies ,lcsh:Q ,Female ,NAD+ kinase ,Oxidation-Reduction ,030217 neurology & neurosurgery - Abstract
Dysregulation in NAD+/NADH levels is associated with increased cell division and elevated levels of reactive oxygen species in rapidly proliferating cancer cells. Conversion of the ketone body acetoacetate (AcAc) to β-hydroxybutyrate (β-HB) by the mitochondrial enzyme β-hydroxybutyrate dehydrogenase (BDH) depends upon NADH availability. The β-HB-to-AcAc ratio is therefore expected to reflect mitochondrial redox. Previous studies reported the potential of hyperpolarized 13C-AcAc to monitor mitochondrial redox in cells, perfused organs and in vivo. However, the ability of hyperpolarized 13C-AcAc to cross the blood brain barrier (BBB) and its potential to monitor brain metabolism remained unknown. Our goal was to assess the value of hyperpolarized [1,3-13C2]AcAc in healthy and tumor-bearing mice in vivo. Following hyperpolarized [1,3-13C2]AcAc injection, production of [1,3-13C2]β-HB was detected in normal and tumor-bearing mice. Significantly higher levels of [1-13C]AcAc and lower [1-13C]β-HB-to-[1-13C]AcAc ratios were observed in tumor-bearing mice. These results were consistent with decreased BDH activity in tumors and associated with increased total cellular NAD+/NADH. Our study confirmed that AcAc crosses the BBB and can be used for monitoring metabolism in the brain. It highlights the potential of AcAc for future clinical translation and its potential utility for monitoring metabolic changes associated with glioma, and other neurological disorders.
- Published
- 2019
74. In vivo investigation of hyperpolarized [1,3
- Author
-
Chloé, Najac, Marina, Radoul, Lydia M, Le Page, Georgios, Batsios, Elavarasan, Subramani, Pavithra, Viswanath, Anne Marie, Gillespie, and Sabrina M, Ronen
- Subjects
Mice ,Magnetic Resonance Spectroscopy ,Spectrophotometry ,Animals ,Brain ,Female ,Glioma ,Oxidation-Reduction ,Article ,Acetoacetates ,Mitochondria - Abstract
Dysregulation in NAD+/NADH levels is associated with increased cell division and elevated levels of reactive oxygen species in rapidly proliferating cancer cells. Conversion of the ketone body acetoacetate (AcAc) to β-hydroxybutyrate (β-HB) by the mitochondrial enzyme β-hydroxybutyrate dehydrogenase (BDH) depends upon NADH availability. The β-HB-to-AcAc ratio is therefore expected to reflect mitochondrial redox. Previous studies reported the potential of hyperpolarized 13C-AcAc to monitor mitochondrial redox in cells, perfused organs and in vivo. However, the ability of hyperpolarized 13C-AcAc to cross the blood brain barrier (BBB) and its potential to monitor brain metabolism remained unknown. Our goal was to assess the value of hyperpolarized [1,3-13C2]AcAc in healthy and tumor-bearing mice in vivo. Following hyperpolarized [1,3-13C2]AcAc injection, production of [1,3-13C2]β-HB was detected in normal and tumor-bearing mice. Significantly higher levels of [1-13C]AcAc and lower [1-13C]β-HB-to-[1-13C]AcAc ratios were observed in tumor-bearing mice. These results were consistent with decreased BDH activity in tumors and associated with increased total cellular NAD+/NADH. Our study confirmed that AcAc crosses the BBB and can be used for monitoring metabolism in the brain. It highlights the potential of AcAc for future clinical translation and its potential utility for monitoring metabolic changes associated with glioma, and other neurological disorders.
- Published
- 2018
75. CBMT-32. IMAGING A HALLMARK OF CANCER: TERT EXPRESSION LEADS TO MRS-DETECTABLE METABOLIC REPROGRAMMING
- Author
-
Russell O. Pieper, Sabrina M. Ronen, and Pavithra Viswanath
- Subjects
Cancer Research ,Abstracts ,Oncology ,business.industry ,Metabolic reprogramming ,medicine ,Cancer research ,Cancer ,Neurology (clinical) ,medicine.disease ,business - Abstract
Hotspot promoter mutations reactivate expression of telomerase reverse transcriptase (TERT) in mutant IDH1 oligodendrogliomas. TERT expression allows glioma cells to avoid telomere dysfunction-induced senescence, thereby enabling limitless proliferation. Since TERT expression is essential for glioma proliferation and TERT inhibitors are attractive therapeutic targets, identification of metabolic biomarkers of TERT expression will facilitate non-invasive imaging of tumor status and response to therapy. Therefore, the goal of this study was to identify (1)H- and hyperpolarized (13)C-magnetic resonance spectroscopy (MRS)-detectable metabolic biomarkers of TERT expression in mutant IDH1 glioma cells. We studied mutant IDH1-expressing immortalized normal human astrocytes without (NHA(pre)) and with TERT expression (NHA(post) and NHA(tert)). Using (1)H-MRS we monitored steady-state metabolite levels and analyzed the data in an unbiased manner using principal component analysis. Our results indicated that the metabolic profile of NHA(pre) cells differed significantly from that of NHA(post) and NHA(tert). Elevated levels of glutathione (GSH, reduced), NADPH, NADH, aspartate and taurine in NHA(post) and NHA(tert) cells relative to NHA(pre) were responsible for this discrimination. These results identify (1)H-MRS-detectable biomarkers of TERT expression in mutant IDH1 glioma cells. Next, we used (13)C-MRS to examine [2-(13)C]-glucose flux to the pentose phosphate pathway (PPP) since the PPP is a major source of NADPH, which, in turn, maintains GSH levels. PPP fractional flux was significantly higher in NHA(post) and NHA(tert) cells relative to NHA(pre), consistent with higher levels of NADPH and GSH in the TERT-expressing models. Importantly, the flux of hyperpolarized [U-(13)C]-glucose to the PPP intermediate 6-phosphogluconate was elevated in NHA(post) and NHA(tert) cells relative to NHA(pre), thereby identifying hyperpolarized [U-(13)C]-glucose as a potential imaging biomarker of TERT status. Collectively, our study links TERT expression to significant metabolic reprogramming in mutant IDH1 gliomas and identifies (1)H- and hyperpolarized (13)C-MRS biomarkers that may be valuable for monitoring tumor TERT status and response to therapy.
- Published
- 2018
76. EXTH-76. (1)H AND HYPERPOLARIZED (13)C MRS BIOMARKERS OF IDH1 MUTANT GLIOMA RESPONSE TO TEMOZOLOMIDE THERAPY
- Author
-
Russell O. Pieper, Pavithra Viswanath, Marina Radoul, Chloé Najac, Elavarasan Subramani, Sabrina M. Ronen, Georgios Batsios, and Anne Marie Gillespie
- Subjects
Cancer Research ,Temozolomide ,IDH1 ,business.industry ,Mutant ,Hyperpolarized 13c ,medicine.disease ,Abstracts ,Isocitrate dehydrogenase ,Oncology ,Metabolic disturbance ,Glioma ,medicine ,Cancer research ,Neurology (clinical) ,business ,medicine.drug ,Glioblastoma - Abstract
The alkylating agent temozolomide (TMZ), previously reserved for treatment of glioblastoma, is now being considered for the treatment of low-grade glioma that are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene. Though the treatment of IDH1 mutant patients with TMZ improves survival, there is a need for metabolic imaging to help in assessing early response to therapy. The goal of this study was, therefore, to determine the value of magnetic resonance spectroscopy (MRS)-based biomarkers for detection of response to treatment. To address this, we examined the global metabolic alterations that occurred following TMZ treatment in a genetically engineered IDH1 mutant immortalized normal human astrocyte cell line (NHAIDHmut) using (1)H and (13)C MRS combined with chemometrics. Cells were treated either with the IC50 of TMZ (100 μM; N=5), or with DMSO (0.2%; N=5) for 72 hours. Then, metabolites were extracted from cells and (1)H spectra acquired. Data were analyzed using SIMCA and the most significant metabolites contributing to class separation were identified using multivariate and univariate analyses. Alternatively, live cells were exposed to hyperpolarized 2-(13)C-pyruvate and dynamic sets of (13)C-MRS spectra recorded to monitor the production of 5-(13)C-glutamate over time. (1)H MRS showed that glutamine, glutamate, pyruvate, succinate, glucose, phosphocholine, isoleucine, valine, lysine, phenylalanine, NAD+/NADP+ and ATP/ADP/AMP were significantly higher in TMZ-treated cells as compared to controls. Accordingly, the tricarboxylic acid (TCA) cycle was identified as a significantly altered pathway following TMZ treatment. Consistent with this finding, dynamically probing the metabolism of hyperpolarized 2-(13)C-pyruvate revealed that build-up of 5-(13)C-glutamate, which is associated with flux to the TCA cycle, was significantly higher in TMZ-treated cells as compared to controls. Further studies are warranted for validation of our findings in other mutant IDH1 models. Nonetheless, our findings identify potential MRS-detectable early biomarkers of response to TMZ therapy in mutant IDH1 glioma.
- Published
- 2018
77. EXTH-35. IN VIVO (1)H MRS DETECTS REDUCED 2HG PRODUCTION IN IDH1 MUTANT GLIOMAS TREATED WITH A DUAL PI3K/MTOR INHIBITOR
- Author
-
Joanna J. Phillips, Pavithra Viswanath, Elavarasan Subramani, Sabrina M. Ronen, Anne Marie Gillespie, Georgios Batsios, and Russell O. Pieper
- Subjects
Cancer Research ,Phosphoinositide 3-kinase ,IDH1 ,biology ,Chemistry ,Mutant ,medicine.disease ,medicine.disease_cause ,Abstracts ,Isocitrate dehydrogenase ,Oncology ,In vivo ,Glioma ,medicine ,biology.protein ,Cancer research ,Neurology (clinical) ,Carcinogenesis ,PI3K/AKT/mTOR pathway - Abstract
70–90% of low-grade gliomas and secondary glioblastomas are characterized by mutations in isocitrate dehydrogenase (IDH1mut). Mutant IDH produces the oncometabolite 2-hydroxyglutarate (2HG), which drives tumorigenesis. Inhibitors of phosphoinositide-3-kinase (PI3K) pathway are currently under clinical investigation for IDH1mut gliomas with positive outcome results, but early response imaging biomarkers are missing. The goal of this study was to identify potential magnetic resonance (MR) detectable biomarkers of IDH1mut glioma response to the dual PI3K/mammalian target of rapamycin (mTOR) inhibitor XL765. We used two genetically-engineered IDH1mut models: a U87 glioblastoma-based model (U87IDHmut) and an immortalized normal human astrocyte-based model (NHAIDHmut), as well as a patient derived IDH1mut model (BT142). The reduction of PI3K/mTOR pathway signaling was validated with western blots of p4E-BP1 for all models. We then used MR spectroscopy (MRS) to investigate the impact of treatment on cell metabolism. Using (1)H-MRS, we observed that XL765 induced a significant ~70% and ~50% reduction in steady-state levels of 2HG and glutamate in U87IDHmut while in NHAIDHmut the drop was ~90% and ~70% for 2HG and glutamate respectively. In the case of BT142 there was a ~35% drop in glutamate levels while 2HG was MRS undetectable in both groups. The translatability of our findings was evaluated in mice bearing orthotropic U87IDHmut xerographs treated with XL765 orally twice a day. XL765-treatment of mice led to an apparent slower tumor growth, which was associated with significantly increased animal survival. Importantly, in vivo (1)H-MRS spectroscopy showed a significant reduction in 2HG levels. The results were verified by (1)H-MRS of tumor extracts. Collectively, our results indicate that treatment with XL765 is associated with response in IDH1mut models. To our knowledge, this is the first time in vivo (1)H-MRS detected reduction in 2HG in gliomas undergoing treatment with a non-IDH1mut-specific inhibitor. Thus, 2HG could potentially be used as a response biomarker.
- Published
- 2018
78. BIMG-08. DEUTERIUM MAGNETIC RESONANCE SPECTROSCOPY USING 2H-PYRUVATE ALLOWS NON-INVASIVE IN VIVO IMAGING OF TERT EXPRESSION IN BRAIN TUMORS
- Author
-
Pavithra Viswanath, Joseph F. Costello, Meryssa Tran, Anne Marie Gillespie, Georgios Batsios, Céline Taglang, and Sabrina M. Ronen
- Subjects
Nuclear magnetic resonance ,Deuterium ,Chemistry ,Non invasive ,AcademicSubjects/MED00300 ,Metabolic Biomarkers and Imaging ,AcademicSubjects/MED00310 ,Nuclear magnetic resonance spectroscopy ,Preclinical imaging ,Supplement Abstracts - Abstract
Telomere shortening constitutes a natural barrier to uncontrolled proliferation and all tumors must find a mechanism of maintaining telomere length. Most human tumors, including high-grade primary glioblastomas (GBMs) and low-grade oligodendrogliomas (LGOGs) achieve telomere maintenance via reactivation of the expression of telomerase reverse transcriptase (TERT), which is silenced in normal somatic cells. TERT expression is, therefore, a driver of tumor proliferation and, due to this essential role, TERT is also a therapeutic target. However, non-invasive methods of imaging TERT are lacking. The goal of this study was to identify magnetic resonance spectroscopy (MRS)-detectable metabolic biomarkers of TERT expression that will enable non-invasive visualization of tumor burden in LGOGs and GBMs. First, we silenced TERT expression by RNA interference in patient-derived LGOG (SF10417, BT88) and GBM (GS2) models. Our results linked TERT silencing to significant reductions in steady-state levels of NADH in all models. NADH is essential for the conversion of pyruvate to lactate, suggesting that measuring pyruvate flux to lactate could be useful for imaging TERT status. Recently, deuterium (2H)-MRS has emerged as a novel, clinically translatable method of monitoring metabolic fluxes in vivo. However, to date, studies have solely examined 2H-glucose and the use of [U-2H]pyruvate for non-invasive 2H-MRS has not been tested. Following intravenous injection of a bolus of [U-2H]pyruvate, lactate production was higher in mice bearing orthotopic LGOG (BT88 and SF10417) and GBM (GS2) tumor xenografts relative to tumor-free mice, suggesting that [U-2H]pyruvate has the potential to monitor TERT expression in vivo. In summary, our study, for the first time, shows the feasibility and utility of [U-2H]pyruvate for in vivo imaging. Importantly, since 2H-MRS can be implemented on clinical scanners, our results provide a novel, non-invasive method of integrating information regarding a fundamental cancer hallmark, i.e. TERT, into glioma patient management.
- Published
- 2021
79. BIMG-02. IMAGING IMMORTALITY: TERT EXPRESSION ALTERS GLUCOSE METABOLISM IN LOW-GRADE GLIOMAS IN A MANNER THAT CAN BE LEVERAGED FOR NONINVASIVE METABOLIC IMAGING
- Author
-
Hema Artee Luchman, Georgios Batsios, Russell O. Pieper, Joseph F. Costello, Pavithra Viswanath, Sabrina M. Ronen, and Anne Marie Gillespie
- Subjects
Chemistry ,Metabolic imaging ,Cancer research ,AcademicSubjects/MED00300 ,Metabolic Biomarkers and Imaging ,AcademicSubjects/MED00310 ,Carbohydrate metabolism ,Supplement Abstracts - Abstract
Telomerase reverse transcriptase (TERT) is essential for tumor immortality and uncontrolled proliferation, including in low-grade oligodendrogliomas (LGOGs). Since it is silenced in somatic cells, TERT is also a therapeutic target. Non-invasive imaging of TERT can differentiate tumor from normal brain or lesions such as gliosis and allow assessment of response to therapy. The goal of this study was to identify magnetic resonance spectroscopy (MRS)-detectable metabolic alterations associated with TERT that can be leveraged for noninvasive imaging in LGOGs. We examined patient-derived BT54 neurospheres in which TERT expression was silenced by RNA interference. 1H-MRS showed that steady-state levels of NAD(P)/H, glutathione, aspartate and AXP were elevated in BT54TERT+ neurospheres relative to BT54TERT-. Glucose flux through the pentose phosphate pathway (PPP) is essential for generating NADPH, which maintains glutathione homeostasis. 13C-MRS confirmed that [2-13C]-glucose flux through the PPP was elevated in BT54TERT+ neurospheres relative to BT54TERT-, an effect associated with higher activity of the PPP enzyme glucose-6-phosphate dehydrogenase (G6PDH). Hyperpolarized 13C-MRS is a method of increasing the signal to noise ratio of 13C-MRS such that it can monitor metabolic fluxes noninvasively in cells, animals and patients. Consistent with elevated PPP flux and G6PDH activity, hyperpolarized [U-13C]-glucose metabolism via the PPP to 6-phosphogluconate (6-PG) was elevated in BT54TERT+ neurospheres relative to BT54TERT-. Importantly, examination of an additional patient-derived LGOG model, the SF10417 model which readily forms orthotopic tumor xenografts in rats, showed that 6-PG production from hyperpolarized [U-13C]-glucose demarcated tumor from normal brain. Furthermore, LGOG patient biopsies had elevated NAD(P)/H, glutathione, aspartate, AXP and G6PDH activity relative to gliosis biopsies, confirming the clinical validity of our observations. Collectively, we have identified a metabolic signature of TERT expression that can be leveraged via hyperpolarized [U-13C]-glucose to improve diagnosis and treatment response monitoring for LGOG patients.
- Published
- 2021
80. TBMT-01. HYPERPOLARIZED δ-[1-13C]GLUCONOLACTONE MONITORS TERT-INDUCED ELEVATION IN PENTOSE PHOSPHATE PATHWAY FLUX IN BRAIN TUMORS IN VIVO
- Author
-
Robert R. Flavell, Peder E. Z. Larson, Pavithra Viswanath, Céline Taglang, Georgios Batsios, Russell O. Pieper, Joseph F. Costello, and Sabrina M. Ronen
- Subjects
Chemistry ,Metabolism ,Pentose phosphate pathway ,medicine.disease ,Blood–brain barrier ,Gluconolactone ,Supplement Abstracts ,Technologies for Studying Brain Metabolism ,medicine.anatomical_structure ,In vivo ,Glioma ,medicine ,Biophysics ,AcademicSubjects/MED00300 ,Low-Grade Glioma ,AcademicSubjects/MED00310 ,Flux (metabolism) - Abstract
Telomerase reverse transcriptase (TERT) expression is essential for tumor proliferation and is an attractive therapeutic target for gliomas. TERT expression has previously been shown to enhance glucose flux via the pentose phosphate pathway (PPP) in low grade gliomas expressing TERT. Hyperpolarized δ-[1-13C]gluconolactone has been used to detect flux via the PPP by monitoring its conversion to 6-phospho-[1-13C]gluconate (6PG) in isolated perfused liver. The goal of our study was to evaluate whether hyperpolarized δ-[1-13C]gluconolactone can be used to monitor elevated PPP flux induced by TERT expression in low grade gliomas, thereby providing a non-invasive method of assessing TERT expression in vivo. Immortalized normal human astrocytes without (NHApre) and with TERT expression (NHApost) were used in cell bioreactor experiments. In vivo experiment with rats bearing orthotopic NHApost or patient-derived low-grade oligodendroglioma (SF10417) tumors were contacted. Dynamic 13C MR spectra were acquired at 14T (cells) or 3T (rats) following injection of hyperpolarized δ-[1-13C]gluconolactone. NHApost cells showed significantly higher flux through the PPP compared to NHApre. This finding was in agreement with previous results indicating that TERT expression elevates PPP flux. In all rats δ-[1-13C]gluconolactone and 6PG were observed indicating that δ-[1-13C]gluconolactone crosses the blood-brain barrier and is rapidly metabolized. Furthermore, both models presented homogeneous distribution of δ-[1-13C]gluconolactone in the brain and higher ratio of 6PG-to-δ-[1-13C]gluconolactone in the tumor area. In summary we show in vivo that hyperpolarized δ-[1-13C]gluconolactone metabolism to 6-phospho-[1-13C]gluconate is significantly higher in tumor compared to contralateral normal brain in TERT-expressing genetically-engineered and patient-derived low-grade oligodendrogliomas. Due to its fundamental role in tumor proliferation, TERT is both a tumor biomarker and a therapeutic target. Monitoring HP δ-[1-13C]gluconolactone metabolism, therefore, has the potential to inform on tumor burden and response to therapy in the clinic.
- Published
- 2021
81. Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
- Author
-
Chloé Najac, Joseph F. Costello, Sabrina M. Ronen, Donghyun Hong, Marina Radoul, Anne Marie Gillespie, Russell O. Pieper, Pavithra Viswanath, and Hema Artee Luchman
- Subjects
0301 basic medicine ,1H-MRS ,IDH1 ,Endocrinology, Diabetes and Metabolism ,Clinical Sciences ,Mutant ,lcsh:QR1-502 ,Biochemistry ,Article ,lcsh:Microbiology ,Analytical Chemistry ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,In vivo ,glioma ,Glioma ,medicine ,noninvasive metabolic biomarkers ,Molecular Biology ,Cancer ,H-1-MRS ,screening and diagnosis ,mutant IDH inhibitor ,business.industry ,Neurosciences ,Glutamate receptor ,medicine.disease ,Brain Disorders ,4.1 Discovery and preclinical testing of markers and technologies ,Brain Cancer ,Glutamine ,Detection ,030104 developmental biology ,Isocitrate dehydrogenase ,5.1 Pharmaceuticals ,030220 oncology & carcinogenesis ,Drug delivery ,Cancer research ,Biochemistry and Cell Biology ,Development of treatments and therapeutic interventions ,business - Abstract
Approximately 80% of low-grade glioma (LGGs) harbor mutant isocitrate dehydrogenase 1/2 (IDH1/2) driver mutations leading to accumulation of the oncometabolite 2-hydroxyglutarate (2-HG). Thus, inhibition of mutant IDH is considered a potential therapeutic target. Several mutant IDH inhibitors are currently in clinical trials, including AG-881 and BAY-1436032. However, to date, early detection of response remains a challenge. In this study we used high resolution 1H magnetic resonance spectroscopy (1H-MRS) to identify early noninvasive MR (Magnetic Resonance)-detectable metabolic biomarkers of response to mutant IDH inhibition. In vivo 1H-MRS was performed on mice orthotopically-implanted with either genetically engineered (U87IDHmut) or patient-derived (BT257 and SF10417) mutant IDH1 cells. Treatment with either AG-881 or BAY-1436032 induced a significant reduction in 2-HG. Moreover, both inhibitors led to a significant early and sustained increase in glutamate and the sum of glutamate and glutamine (GLX) in all three models. A transient early increase in N-acetylaspartate (NAA) was also observed. Importantly, all models demonstrated enhanced animal survival following both treatments and the metabolic alterations were observed prior to any detectable differences in tumor volume between control and treated tumors. Our study therefore identifies potential translatable early metabolic biomarkers of drug delivery, mutant IDH inhibition and glioma response to treatment with emerging clinically relevant therapies.
- Published
- 2021
82. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
- Author
-
Russell O. Pieper, Shigeo Ohba, Joydeep Mukherjee, Tor-Christian Aase Johannessen, Sabrina M. Ronen, Rolf Bjerkvig, and Pavithra Viswanath
- Subjects
0301 basic medicine ,Cancer Research ,Mutant ,Benzeneacetamides ,Cell Transformation ,medicine.disease_cause ,Histones ,0302 clinical medicine ,Histone methylation ,Cells, Cultured ,Cancer ,Mutation ,Cultured ,Tumor ,biology ,Brain Neoplasms ,Imidazoles ,Glioma ,Methylation ,Isocitrate Dehydrogenase ,Cell Transformation, Neoplastic ,Histone ,Oncology ,030220 oncology & carcinogenesis ,Cells ,Oncology and Carcinogenesis ,Article ,Cell Line ,Glutarates ,03 medical and health sciences ,Rare Diseases ,Cell Line, Tumor ,Genetics ,medicine ,Humans ,Oncology & Carcinogenesis ,Molecular Biology ,Cell Proliferation ,Neoplastic ,Cell growth ,Human Genome ,Brain Disorders ,Brain Cancer ,030104 developmental biology ,Astrocytes ,Cancer research ,biology.protein ,H3K4me3 ,Carcinogenesis ,Developmental Biology - Abstract
Missense mutations in the active site of isocitrate dehydrogenase 1 (IDH1) biologically and diagnostically distinguish low-grade gliomas and secondary glioblastomas from primary glioblastomas. IDH1 mutations lead to the formation of the oncometabolite 2-hydroxyglutarate (2-HG) from the reduction of α-ketoglutarate (α-KG), which in turn facilitates tumorigenesis by modifying DNA and histone methylation as well blocking differentiation processes. Although mutant IDH1 expression is thought to drive the gliomagenesis process, the extent to which it remains a viable therapeutic target remains unknown. To address this question, we exposed immortalized (p53/pRb deficient), untransformed human astrocytes to the mutant IDH1 inhibitor AGI-5198 prior to, concomitant with, or at intervals after, introduction of transforming mutant IDH1, then measured effects on 2-HG levels, histone methylation (H3K4me3, H3K9me2, H3K9me3, or H3K27me3), and growth in soft agar. Addition of AGI-5198 prior to, or concomitant with, introduction of mutant IDH1 blocked all mutant IDH1-driven changes, including cellular transformation. Addition at time intervals as short as 4 days following introduction of mutant IDH1 also suppressed 2-HG levels, but had minimal effects on histone methylation, and lost the ability to suppress clonogenicity in a time-dependent manner. Furthermore, in two different models of mutant IDH1–driven gliomagenesis, AGI-5198 exposures that abolished production of 2-HG also failed to decrease histone methylation, adherent cell growth, or anchorage-independent growth in soft agar over a prolonged period. These studies show although mutant IDH1 expression drives gliomagenesis, mutant IDH1 itself rapidly converts from driver to passenger. Implications: Agents that target mutant IDH may be effective for a narrow time and may require further optimization or additional therapeutics in glioma. Mol Cancer Res; 14(10); 976–83. ©2016 AACR.
- Published
- 2016
83. Accelerated high-bandwidth MR spectroscopic imaging using compressed sensing
- Author
-
Chloé Najac, Sarah J. Nelson, Peter J. Shin, Peder E. Z. Larson, Peng Cao, Daniel B. Vigneron, Sabrina M. Ronen, Ilwoo Park, and Irene Marco-Rius
- Subjects
medicine.diagnostic_test ,Chemistry ,Magnetic resonance imaging ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Acceleration ,0302 clinical medicine ,Compressed sensing ,Nuclear magnetic resonance ,Undersampling ,In vivo ,Mr spectroscopic imaging ,medicine ,High bandwidth ,Radiology, Nuclear Medicine and imaging ,Molecular imaging ,030217 neurology & neurosurgery - Abstract
Purpose To develop a compressed sensing (CS) acceleration method with a high spectral bandwidth exploiting the spatial-spectral sparsity of MR spectroscopic imaging (MRSI). Methods Accelerations were achieved using blip gradients during the readout to perform nonoverlapped and stochastically delayed random walks in kx-ky-t space, combined with block-Hankel matrix completion for efficient reconstruction. Both retrospective and prospective CS accelerations were applied to 13C MRSI experiments, including in vivo rodent brain and liver studies with administrations of hyperpolarized [1-13C] pyruvate at 7.0 Tesla (T) and [2-13C] dihydroxyacetone at 3.0 T, respectively. Results In retrospective undersampling experiments using in vivo 7.0 T data, the proposed method preserved spectral, spatial, and dynamic fidelities with R2 ≥ 0.96 and ≥ 0.87 for pyruvate and lactate signals, respectively, 750-Hz spectral separation, and up to 6.6-fold accelerations. In prospective in vivo experiments, with 3.8-fold acceleration, the proposed method exhibited excellent spatial localization of metabolites and peak recovery for pyruvate and lactate at 7.0 T as well as for dihydroxyacetone and its metabolic products with a 4.5-kHz spectral span (140 ppm at 3.0 T). Conclusions This study demonstrated the feasibility of a new CS approach to accelerate high spectral bandwidth MRSI experiments. Magn Reson Med, 2016. © 2016 Wiley Periodicals, Inc.
- Published
- 2016
84. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters
- Author
-
Chibo Hong, Aleksandr Pankov, Russell O. Pieper, Pavithra Viswanath, Chloé Najac, Sabrina M. Ronen, Pia Eriksson, Jose L. Izquierdo-Garcia, and Joseph F. Costello
- Subjects
0301 basic medicine ,mutant IDH1 ,Monocarboxylic Acid Transporters ,IDH1 ,Mutant ,Down-Regulation ,Muscle Proteins ,MCT4 ,MCT1 ,Biology ,03 medical and health sciences ,Downregulation and upregulation ,Glioma ,medicine ,metabolic reprogramming ,Humans ,Symporters ,Brain Neoplasms ,Transporter ,Pyruvate dehydrogenase complex ,medicine.disease ,Molecular biology ,magnetic resonance spectroscopy ,Isocitrate Dehydrogenase ,3. Good health ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Isocitrate dehydrogenase ,Oncology ,Biochemistry ,Symporter ,Mutation ,Research Paper - Abstract
// Pavithra Viswanath 1 , Chloe Najac 1 , Jose L. Izquierdo-Garcia 1 , Aleksandr Pankov 2 , Chibo Hong 2 , Pia Eriksson 1 , Joseph F. Costello 2 , Russell O. Pieper 2 , Sabrina M. Ronen 1 1 Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA 2 Department of Neurological Surgery, Helen Diller Research Center, University of California San Francisco, San Francisco, CA 94143, USA Correspondence to: Sabrina Ronen, e-mail: sabrina.ronen@ucsf.edu Keywords: MCT1, MCT4, mutant IDH1, metabolic reprogramming, magnetic resonance spectroscopy Received: February 05, 2016 Accepted: April 10, 2016 Published: April 26, 2016 ABSTRACT Mutations in isocitrate dehydrogenase 1 (IDH1) are characteristic of low-grade gliomas. We recently showed that mutant IDH1 cells reprogram cellular metabolism by down-regulating pyruvate dehydrogenase (PDH) activity. Reduced pyruvate metabolism via PDH could lead to increased pyruvate conversion to lactate. The goal of this study was therefore to investigate the impact of the IDH1 mutation on the pyruvate-to-lactate flux. We used 13 C magnetic resonance spectroscopy and compared the conversion of hyperpolarized [1- 13 C]-pyruvate to [1- 13 C]-lactate in immortalized normal human astrocytes expressing mutant or wild-type IDH1 (NHAIDHmut and NHAIDHwt). Our results indicate that hyperpolarized lactate production is reduced in NHAIDHmut cells compared to NHAIDHwt. This reduction was associated with lower expression of the monocarboxylate transporters MCT1 and MCT4 in NHAIDHmut cells. Furthermore, hyperpolarized lactate production was comparable in lysates of NHAIDHmut and NHAIDHwt cells, wherein MCTs do not impact hyperpolarized pyruvate delivery and lactate production. Collectively, our findings indicated that lower MCT expression was a key contributor to lower hyperpolarized lactate production in NHAIDHmut cells. The SLC16A3 (MCT4) promoter but not SLC16A1 (MCT1) promoter was hypermethylated in NHAIDHmut cells, pointing to possibly different mechanisms mediating reduced MCT expression. Finally analysis of low-grade glioma patient biopsy data from The Cancer Genome Atlas revealed that MCT1 and MCT4 expression was significantly reduced in mutant IDH1 tumors compared to wild-type. Taken together, our study shows that reduced MCT expression is part of the metabolic reprogramming of mutant IDH1 gliomas. This finding could impact treatment and has important implications for metabolic imaging of mutant IDH1 gliomas.
- Published
- 2016
85. Hyperpolarized 13C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring
- Author
-
Chloé Najac, Pavithra Viswanath, Pia Eriksson, Sabrina M. Ronen, Charles Chesnelong, Michael D. Blough, J. Gregory Cairncross, H. Artee Luchman, Marina Radoul, and Myriam M. Chaumeil
- Subjects
0301 basic medicine ,NA, number of averages ,Mutant ,TP53, tumor protein p53 ,FOV, field of view ,PDGF, platelet-derived growth factor ,lcsh:RC346-429 ,chemistry.chemical_compound ,AUC, area under the curve ,0302 clinical medicine ,DNP, dynamic nuclear polarization ,RB1, retinoblastoma protein 1 ,Pyruvic Acid ,Tumor Cells, Cultured ,α-KG, α-ketoglutarate ,TE, echo time ,education.field_of_study ,MCT1, monocarboxylate transporter 1 ,VOI, voxel of interest ,Brain Neoplasms ,MRS, magnetic resonance spectroscopic imaging ,Metabolic reprogramming ,Regular Article ,Glioma ,SNR, signal-to-noise ratio ,Isocitrate dehydrogenase 1 (IDH1) mutation ,Isocitrate Dehydrogenase ,TR, repetition time ,3. Good health ,Isocitrate dehydrogenase ,Neurology ,030220 oncology & carcinogenesis ,SLC16A1, solute carrier family 16 member 1 ,FLAIR, fluid attenuated inversion recovery ,lcsh:R858-859.7 ,Tacq, acquisition time ,PI3K, phosphoinositide 3-kinase ,medicine.drug ,IDH1 ,Cognitive Neuroscience ,Lactate dehydrogenase A ,mTOR, mammalian target of rapamycin ,Biology ,lcsh:Computer applications to medicine. Medical informatics ,IDH1, isocitrate dehydrogenase 1 ,PET, positron emission tomography ,MR, magnetic resonance ,03 medical and health sciences ,In vivo ,medicine ,Biomarkers, Tumor ,Humans ,Radiology, Nuclear Medicine and imaging ,DNP-MR, dynamic nuclear polarization magnetic resonance ,LDHA, lactate dehydrogenase A ,Lactic Acid ,Carbon-13 Magnetic Resonance Spectroscopy ,education ,lcsh:Neurology. Diseases of the nervous system ,EGF, epidermal growth factor ,Hyperpolarized 13C Magnetic Resonance Spectroscopy (MRS) ,Temozolomide ,SW, spectral width ,TMZ, temozolomide ,MRS, magnetic resonance spectroscopy ,medicine.disease ,PBS, phosphate-buffer saline ,PTEN, phosphatase and tensin homolog ,EGFR, epidermal growth factor receptor ,FA, flip angle ,FGF, fibroblast growth factor ,030104 developmental biology ,2-HG, 2-hydroxyglutarate ,chemistry ,MCT4, monocarboxylate transporter 4 ,Cancer research ,NT, number of transients ,SLC16A3, solute carrier family 16 member 3 ,GBM, glioblastoma ,TCGA, The Cancer Genome Atlas ,Neurology (clinical) ,Pyruvic acid ,AIF, arterial input function ,MRI, magnetic resonance imaging - Abstract
Metabolic imaging of brain tumors using 13C Magnetic Resonance Spectroscopy (MRS) of hyperpolarized [1-13C] pyruvate is a promising neuroimaging strategy which, after a decade of preclinical success in glioblastoma (GBM) models, is now entering clinical trials in multiple centers. Typically, the presence of GBM has been associated with elevated hyperpolarized [1-13C] lactate produced from [1-13C] pyruvate, and response to therapy has been associated with a drop in hyperpolarized [1-13C] lactate. However, to date, lower grade gliomas had not been investigated using this approach. The most prevalent mutation in lower grade gliomas is the isocitrate dehydrogenase 1 (IDH1) mutation, which, in addition to initiating tumor development, also induces metabolic reprogramming. In particular, mutant IDH1 gliomas are associated with low levels of lactate dehydrogenase A (LDHA) and monocarboxylate transporters 1 and 4 (MCT1, MCT4), three proteins involved in pyruvate metabolism to lactate. We therefore investigated the potential of 13C MRS of hyperpolarized [1-13C] pyruvate for detection of mutant IDH1 gliomas and for monitoring of their therapeutic response. We studied patient-derived mutant IDH1 glioma cells that underexpress LDHA, MCT1 and MCT4, and wild-type IDH1 GBM cells that express high levels of these proteins. Mutant IDH1 cells and tumors produced significantly less hyperpolarized [1-13C] lactate compared to GBM, consistent with their metabolic reprogramming. Furthermore, hyperpolarized [1-13C] lactate production was not affected by chemotherapeutic treatment with temozolomide (TMZ) in mutant IDH1 tumors, in contrast to previous reports in GBM. Our results demonstrate the unusual metabolic imaging profile of mutant IDH1 gliomas, which, when combined with other clinically available imaging methods, could be used to detect the presence of the IDH1 mutation in vivo., Graphical abstract Image 1, Highlights • Metabolic imaging of mutant IDH1 gliomas using hyperpolarized 13C MRS is described. • In contrast to GBM, mutant IDH1 gliomas produce no hyperpolarized [1-13C] lactate. • Hyperpolarized [1-13C] lactate is not reduced by treatment in mutant IDH1 tumors. • Mutant IDH1 gliomas present an unusual metabolic imaging profile.
- Published
- 2016
86. 1H-13C independently tuned radiofrequency surface coil applied for in vivo hyperpolarized MRI
- Author
-
Sabrina M. Ronen, Sarah J. Nelson, Chloé Najac, Peng Cao, Peder E. Z. Larson, Ilwoo Park, and Xiaoliang Zhang
- Subjects
In vivo magnetic resonance spectroscopy ,Materials science ,Imaging phantom ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Resonator ,0302 clinical medicine ,Nuclear magnetic resonance ,Electromagnetic coil ,Q factor ,Radiology, Nuclear Medicine and imaging ,Hyperpolarization (physics) ,Electrical impedance ,030217 neurology & neurosurgery ,Radiofrequency coil - Abstract
PURPOSE To develop a lump-element double-tuned common-mode-differential-mode (CMDM) radiofrequency (RF) surface coil with independent frequency tuning capacity for MRS and MRI applications. METHODS The presented design has two modes that can operate with different current paths, allowing independent frequency adjustment. The coil prototype was tested on the bench and then examined in phantom and in vivo experiments. RESULTS Standard deviations of frequency and impedance fluctuations measured in one resonator, while changing the tuning capacitor of another resonator, were less than 13 kHz and 0.55 Ω. The unloaded S21 was -36 dB and -41 dB, while the unloaded Q factor was 260 and 287, for 13 C and 1 H, respectively. In vivo hyperpolarized 13 C MR spectroscopy data demonstrated the feasibility of using the CMDM coil to measure the dynamics of lactate, alanine, pyruvate and bicarbonate signal in a normal rat head along with acquiring 1 H anatomical reference images. CONCLUSION Independent frequency tuning capacity was demonstrated in the presented lump-element double-tuned CMDM coil. This CMDM coil maintained intrinsically decoupled magnetic fields, which provided sufficient isolation between the two resonators. The results from in vivo experiments demonstrated high sensitivity of both the 1 H and 13 C resonators. Magn Reson Med 76:1612-1620, 2016. © 2015 International Society for Magnetic Resonance in Medicine.
- Published
- 2015
87. Magnetic Resonance (MR) Metabolic Imaging in Glioma
- Author
-
Myriam M. Chaumeil, Sabrina M. Ronen, and Janine M. Lupo
- Subjects
medicine.diagnostic_test ,business.industry ,General Neuroscience ,Glioma ,Metabolic imaging ,Medicine ,Magnetic resonance imaging ,Neurology (clinical) ,Nuclear magnetic resonance spectroscopy ,business ,Nuclear medicine ,medicine.disease ,Pathology and Forensic Medicine - Abstract
This review is focused on describing the use of magnetic resonance (MR) spectroscopy for metabolic imaging of brain tumors. We will first review the MR metabolic imaging findings generated from preclinical models, focusing primarily on in vivo studies, and will then describe the use of metabolic imaging in the clinical setting. We will address relatively well-established (1) H MRS approaches, as well as (31) P MRS, (13) C MRS and emerging hyperpolarized (13) C MRS methodologies, and will describe the use of metabolic imaging for understanding the basic biology of glioma as well as for improving the characterization and monitoring of brain tumors in the clinic.
- Published
- 2015
88. First hyperpolarized [2-13C]pyruvate MR studies of human brain metabolism
- Author
-
James B. Slater, John Kurhanewicz, Jeremy W. Gordon, Daniel B. Vigneron, Daniele Mammoli, Myriam M. Chaumeil, Chris Suszczynski, Sabrina M. Ronen, Brian Chung, Adam Autry, Chou T. Tan, Robert Bok, Lydia M. Le Page, Peter J. Shin, Peder E. Z. Larson, Yan Li, Susan M. Chang, Hsin-Yu Chen, and Renuka Sriram
- Subjects
Nuclear and High Energy Physics ,Chemistry ,Biophysics ,Glutamate receptor ,Energy metabolism ,Human brain ,Metabolism ,Pharmacology ,010402 general chemistry ,Condensed Matter Physics ,01 natural sciences ,Biochemistry ,030218 nuclear medicine & medical imaging ,0104 chemical sciences ,03 medical and health sciences ,IRB Approval ,0302 clinical medicine ,medicine.anatomical_structure ,Healthy volunteers ,medicine ,Mr studies ,Metabolite kinetics - Abstract
We developed methods for the preparation of hyperpolarized (HP) sterile [2-13C]pyruvate to test its feasibility in first-ever human NMR studies following FDA-IND & IRB approval. Spectral results using this MR stable-isotope imaging approach demonstrated the feasibility of investigating human cerebral energy metabolism by measuring the dynamic conversion of HP [2-13C]pyruvate to [2-13C]lactate and [5-13C]glutamate in the brain of four healthy volunteers. Metabolite kinetics, signal-to-noise (SNR) and area-under-curve (AUC) ratios, and calculated [2-13C]pyruvate to [2-13C]lactate conversion rates (kPL) were measured and showed similar but not identical inter-subject values. The kPL measurements were equivalent with prior human HP [1-13C]pyruvate measurements.
- Published
- 2019
89. CBMT-08. IN VIVO EVALUATION OF PENTOSE PHOSPHATE PATHWAY ACTIVITY IN ORTHOTOPIC GLIOMA USING HYPERPOLARIZED δ-[1-13C]GLUCONOLACTONE
- Author
-
Céline Taglang, Elavarasan Subramani, Robert R. Flavell, Peder E. Z. Larson, Peng Cao, Sabrina M. Ronen, Georgios Batsios, and Pavithra Viswanath
- Subjects
chemistry.chemical_classification ,Cancer Research ,Metabolism ,Pentose phosphate pathway ,medicine.disease ,Cell Biology and Metabolism ,Gluconolactone ,chemistry.chemical_compound ,Oncology ,Biochemistry ,chemistry ,In vivo ,Glioma ,Ribose ,medicine ,Phosphorylation ,Nucleotide ,Neurology (clinical) - Abstract
The pentose phosphate pathway (PPP) generates NADPH and ribose 5-phosphate, which are involved in the scavenging of reactive oxygen species and the synthesis of nucleotides. As such, the PPP is typically upregulated in cancer cells to address the metabolic needs of rapid cell proliferation. Imaging PPP upregulation could therefore be useful in tumor assessment. One intermediate of the pathway is 6-phospho-δ-gluconolactone (6P-δ-GL), which is produced by phosphorylation of δ-gluconolactone. 6P-δ-GL is further metabolized to 6-phospho-gluconate (6PG). The goal of our study was to evaluate, for the first time, whether hyperpolarized (HP) δ-[1-13C]gluconolactone can be used to assess PPP flux and detect the presence of tumor in an orthotopic glioma rat model. Athymic nude rats bearing orthotropic U87 tumors or age-matched tumor-free controls were investigated. HP studies were performed following intravenous injection of HP δ-[1-13C]gluconolactone and metabolic images using a flyback spectral-spatial echo-planar spectroscopic imaging pulse were acquired. The data were processed using in-house Matlab code. 6P-δ-GL and 6-phospho-γ-[1-13C]gluconolactone were observed in all rats ~10 seconds after HP δ-[1-13C]gluconolactone injection, followed ~5 seconds later by production of 6PG observed at 179.3ppm. These data indicate that HP δ-[1-13C]gluconolactone likely crosses the blood-brain barrier, consistent with its transport via glucose transporters, and is rapidly metabolized. Importantly, 6PG was significantly higher in tumor voxels. The ratio of 6PG-to-6P-δ-GL was comparable in normal brain and in normal-appearing contralateral brain of tumor-bearing rats at 0.43±0.09 and 0.45±0.06 respectively (p=0.85), but significant higher in the tumor regions at 0.70±0.11 (p=0.04 and p=0.02 respectively), consistent with the elevated PPP flux that typically occurs in tumor cells. Our results indicate, to our knowledge for the first time, that metabolism of HP δ-[1-13C]gluconolactone can be assessed in the brain and that elevated 6PG production in glioma provides a potential metabolic imaging approach to probe tumor development, recurrence and response to therapy.
- Published
- 2019
90. CBMT-41. IMAGING A HALLMARK OF CANCER: HYPERPOLARIZED 13C-MAGNETIC RESONANCE SPECTROSCOPY CAN NON-INVASIVELY MONITOR TERT EXPRESSION IN LOW-GRADE GLIOMAS IN VIVO
- Author
-
Georgios Batsios, Anne Marie Gillespie, Pavithra Viswanath, Sabrina M. Ronen, and Russell O. Pieper
- Subjects
Cancer Research ,Nuclear magnetic resonance ,Oncology ,In vivo ,Chemistry ,medicine ,Hyperpolarized 13c ,Cancer ,Neurology (clinical) ,Nuclear magnetic resonance spectroscopy ,medicine.disease ,Cell Biology and Metabolism - Abstract
Telomerase reverse transcriptase (TERT) expression is a hallmark of cancer, including in primary glioblastomas and low-grade oligodendrogliomas. Since TERT is essential for glioma proliferation and is an attractive therapeutic target, metabolic imaging of TERT status can inform on tumor progression and response to therapy. To that end, the goal of this study was to identify non-invasive, translational, hyperpolarized 13C-magnetic resonance spectroscopy-detectable metabolic imaging biomarkers of TERT in low-grade oligodendrogliomas. Unbiased metabolomic analysis of immortalized normal human astrocytes without (NHAcontrol) and with TERT (NHAtert) indicated that TERT induced unique metabolic reprogramming. Notably, TERT increased NADPH and NADH levels. Glucose flux through the pentose phosphate pathway (PPP) is a major producer of NADPH. Non-invasive imaging of PPP flux using hyperpolarized [U-13C,U-2H]-glucose indicated that production of the PPP metabolite 6-phosphogluconate (6-PG) was elevated in NHAtert cells relative to NHAcontrol. Importantly, hyperpolarized [U-13C,U-2H]-glucose flux to 6-PG clearly differentiated tumor from normal brain in orthotopic NHAtert tumor xenografts. Next, we exploited the observation that TERT expression increased NADH, which is essential for the metabolism of hyperpolarized [1-13C]-alanine to lactate. Lactate production from hyperpolarized [1-13C]-alanine was higher in NHAtert cells relative to NHAcontrol. Importantly, hyperpolarized [1-13C]-alanine imaging in orthotopic NHAtert tumors revealed pronounced differences in lactate production between tumor tissue and normal brain. Mechanistically, TERT increased expression of glucose-6-phosphate dehydrogenase (G6PDH), the rate-limiting enzyme for 6-PG and NADPH production, and of nicotinamide phosphoribosyltransferase (NAMPT), a rate-limiting enzyme for NADH biosynthesis. Silencing TERT reversed G6PDH and NAMPT expression and normalized hyperpolarized [U-13C,U-2H]-glucose and [1-13C]-alanine metabolism, validating our imaging biomarkers. Finally, hyperpolarized [U-13C,U-2H]-glucose and [1-13C]-alanine could monitor TERT status in the clinically relevant, patient-derived BT54 oligodendroglioma model. In summary, we demonstrate, for the first time, non-invasive in vivo imaging of TERT status in gliomas that can enable longitudinal analysis of tumor burden and treatment response in the clinic.
- Published
- 2019
91. Late-stage deuteration of
- Author
-
Céline, Taglang, David E, Korenchan, Cornelius, von Morze, Justin, Yu, Chloé, Najac, Sinan, Wang, Joseph E, Blecha, Sukumar, Subramaniam, Robert, Bok, Henry F, VanBrocklin, Daniel B, Vigneron, Sabrina M, Ronen, Renuka, Sriram, John, Kurhanewicz, David M, Wilson, and Robert R, Flavell
- Subjects
Article - Abstract
A robust and selective late-stage deuteration methodology was applied to (13)C-enriched amino and alpha hydroxy acids to increase spin-lattice relaxation constant T(1) for hyperpolarized (13)C magnetic resonance imaging. For the five substrates with (13)C-labeling on the C1-position ([1-(13)C]alanine, [1-(13)C]serine, [1-(13)C]lactate, [1-(13)C]glycine, and [1-(13)C]valine), significant increase of their T(1) was observed at 3T with deuterium labeling (+26%, 22%, +16%, +25% and +29%, respectively). Remarkably, in the case of [2-(13)C]alanine, [2-(13)C]serine and [2-(13)C]lactate, deuterium labeling led to a greater than four fold increase in T(1). [1-(13)C,2-(2)H]alanine, produced using this method, was applied to in vitro enzyme assays with alanine aminotransferase, demonstrating a kinetic isotope effect.
- Published
- 2018
92. HDAC inhibition in glioblastoma monitored by hyperpolarized
- Author
-
Marina, Radoul, Chloé, Najac, Pavithra, Viswanath, Joydeep, Mukherjee, Mark, Kelly, Anne Marie, Gillespie, Myriam M, Chaumeil, Pia, Eriksson, Romelyn, Delos Santos, Russell O, Pieper, and Sabrina M, Ronen
- Subjects
Monocarboxylic Acid Transporters ,Vorinostat ,Symporters ,Mice, Nude ,Muscle Proteins ,Acetylation ,Magnetic Resonance Imaging ,Survival Analysis ,Article ,Histone Deacetylase Inhibitors ,Histones ,Bioreactors ,Cell Line, Tumor ,Pyruvic Acid ,Metabolome ,Animals ,Female ,Lactic Acid ,Carbon-13 Magnetic Resonance Spectroscopy ,Glioblastoma ,Cell Proliferation - Abstract
Vorinostat is a histone deacetylase (HDAC) inhibitor that inhibits cell proliferation and induces apoptosis in solid tumors and is in clinical trials for the treatment of glioblastoma (GBM). The goal of this study was to assess whether hyperpolarized (13)C Magnetic Resonance Spectroscopy (MRS) and Magnetic Resonance Spectroscopic Imaging (MRSI) can detect HDAC inhibition in GBM models. First, we confirmed HDAC inhibition in U87 GBM cells and evaluated real-time dynamic metabolic changes using a bioreactor system with live Vorinostat-treated or control cells. We found a significant 40% decrease in the (13)C MRS-detectable ratio of hyperpolarized [1-(13)C]lactate to hyperpolarized [1-(13)C]pyruvate, [1-(13)C]Lac/Pyr, and a 37% decrease in the pseudo-rate constant, k(PL), for hyperpolarized [1-(13)C]lactate production, in Vorinostat-treated cells compared to controls. To understand the underlying mechanism for this finding, we assessed the expression and activity of lactate dehydrogenase (LDH), which catalyzes the pyruvate to lactate conversion, its associated cofactor nicotinamide adenine dinucleotide (NADH), the expression of monocarboxylate transporters (MCTs) MCT1 and MCT4, that shuttle pyruvate and lactate in and out of the cell, and intracellular lactate levels. We found that the most likely explanation for our finding that hyperpolarized lactate is reduced in treated cells, is a 30% reduction in intracellular lactate levels that occurs as a result of increased expression of both MCT1 and MCT4 in Vorinostat-treated cells. In vivo (13)C MRSI studies of orthotopic tumors in mice also showed a significant 52% decrease in hyperpolarized [1-(13)C]Lac/Pyr when comparing Vorinostat-treated U87 GBM tumors to controls, and, as in the cell studies, this metabolic finding was associated with increased MCT1 and MCT4 expression in HDAC-inhibited tumors. Thus, the (13)C MRSI-detectable decrease in hyperpolarized [1-(13)C]lactate production could serve as a biomarker of response to HDAC inhibitors.
- Published
- 2018
93. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
- Author
-
Joanna J. Phillips, Jose L. Izquierdo-Garcia, Russell O. Pieper, Pavithra Viswanath, J. Gregory Cairncross, Hema Artee Luchman, Marina Radoul, Sabrina M. Ronen, National Institutes of Health (United States), and National Institutes of Health (Estados Unidos)
- Subjects
0301 basic medicine ,Choline kinase ,IDH1 ,HIF-1α ,lcsh:RC254-282 ,Brain tumors ,IDH1 mutation ,03 medical and health sciences ,chemistry.chemical_compound ,Rare Diseases ,Downregulation and upregulation ,In vivo ,Clinical Research ,Glioma ,Magnetic resonance spectroscopy ,medicine ,Phosphoethanolamine ,Phosphocholine ,Cancer ,Ethanolamine kinase ,Chemistry ,Research ,HIF-1 alpha ,Metabolic reprogramming ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,2-Hydroxyglutarate ,Molecular biology ,3. Good health ,Brain Disorders ,Brain Cancer ,Psychiatry and Mental health ,030104 developmental biology ,Isocitrate dehydrogenase ,Biotechnology - Abstract
Background: Magnetic resonance spectroscopy (MRS) studies have identified elevated levels of the phospholipid precursor phosphocholine (PC) and phosphoethanolamine (PE) as metabolic hallmarks of cancer. Unusually, however, PC and PE levels are reduced in mutant isocitrate dehydrogenase 1 (IDHmut) gliomas that produce the oncometabolite 2-hydroxyglutarate (2-HG) relative to wild-type IDH1 (IDHwt) gliomas. The goal of this study was to determine the molecular mechanism underlying this unusual metabolic reprogramming in IDHmut gliomas. Methods: Steady-state PC and PE were quantified using 31P-MRS. To quantify de novo PC and PE synthesis, we used 13C-MRS and measured flux to 13C-PC and 13C-PE in cells incubated with [1,2-13C]-choline and [1,2-13C]-ethanolamine. The activities of choline kinase (CK) and ethanolamine kinase (EK), the enzymes responsible for PC and PE synthesis, were quantified using 31P-MR-based assays. To interrogate the role of 2-HG, we examined IDHwt cells incubated with 2-HG and, conversely, IDHmut cells treated with the IDHmut inhibitor AGI-5198. To examine the role of hypoxia-inducible factor 1-α (HIF-1α), we silenced HIF-1α using RNA interference. To confirm our findings in vivo and in the clinic, we studied IDHwt and IDHmut orthotopic tumor xenografts and glioma patient biopsies. Results: De novo synthesis of PC and PE was reduced in IDHmut cells relative to IDHwt. Concomitantly, CK activity and EK activity were reduced in IDHmut cells. Pharmacological manipulation of 2-HG levels established that 2-HG was responsible for reduced CK activity, EK activity, PC and PE. 2-HG has previously been reported to stabilize levels of HIF-1α, a known regulator of CK activity. Silencing HIF-1α in IDHmut cells restored CK activity, EK activity, PC and PE to IDHwt levels. Our findings were recapitulated in IDHmut orthotopic tumor xenografts and, most importantly, in IDHmut patient biopsies, validating our findings in vivo and in the clinic. Conclusions: This study identifies, to our knowledge for the first time, a direct role for 2-HG in the downregulation of CK and EK activity, and thereby, PC and PE synthesis in IDHmut gliomas. These results highlight the unusual reprogramming of phospholipid metabolism in IDHmut gliomas and have implications for the identification of MRS-detectable metabolic biomarkers associated with 2-HG status. This work was supported by the following grants: NIH R01CA172845 (SMR), NIH R01CA197254 (SMR), NIH R01CA154915 (SMR), FP7/2007-2013 REA600396 (JLI), SAF2014-59118-JIN (JLI), UCSF Brain Tumor Loglio Collective (SMR, ROP, JJP), NICO (SMR), UCSF Brain Tumor Research Center SPORE Tissue Core (P50CA97257) and UCSF Brain Tumor Research Center SPORE Career Development Grant (P50CA97257 to PV). Sí
- Published
- 2018
94. METB-14. DOWN-REGULATION OF ACETATE METABOLISM TOWARDS FATTY ACIDS IN IDH1 MUTANT GLIOMA
- Author
-
Chloé Najac, Sabrina M. Ronen, Marina Radoul, Myriam M. Chaumeil, and Pavithra Viswanath
- Subjects
Cancer Research ,IDH1 ,Chemistry ,Mutant ,medicine.disease ,Acetate metabolism ,Glutamine ,Abstracts ,Oncology ,Biochemistry ,Downregulation and upregulation ,Glioma ,medicine ,Neurology (clinical) - Abstract
Acetate has recently been identified as a major alternative source of nutrients for glioblastoma and brain metastases. After cellular uptake, acetate is converted to acetyl-CoA, a key metabolic intermediate that fuels the TCA cycle and is an essential building block for the biosynthesis of fatty acids. Interestingly, the potential role of acetate in lower-grade glioma harboring the isocitrate dehydrogenase 1 mutation has not yet been elucidated. The goal of this study was therefore to investigate the role of acetate in fatty acid biosynthesis using a well-characterized genetically-engineered cell model that overexpresses either wild-type IDH1 (IDHwt) or mutant IDH1 (IDHmut): an immortalized normal human astrocyte (NHA)-based model. We used 1H and 13C magnetic resonance spectroscopy to quantify the flux of [1,2-13C]-acetate to 13C fatty acids. Our results indicated that the total levels of fatty acids were not significantly different between IDHmut and IDHwt NHA cells. However, the flux of 13C-labeled acetate towards fatty acids was significantly reduced by ~60% in IDHmut NHA cells relative to IDHwt NHA cells. To investigate this disconnect and understand the underlying biological mechanisms, we performed cell biological assays. Surprisingly, this decrease in acetate metabolism was associated with a drop in fatty acid synthase and ATP citrate lyase expressions, two enzymes involved in fatty acid synthesis from acetyl-CoA, in IDHmut NHA cells, whereas expression of acetyl-CoA synthase (AceS1), the cytosolic enzyme converting acetate to acetyl-CoA, was not altered. Asignificant drop in lipid droplet accumulation was also observed in IDHmut NHA cells as indicated using a spectrophotometric assay. Taken together, this points to alternate sources for fatty acids (e.g. glucose, glutamine, uptake from serum) in IDH1mut cells and suggests that fatty acids are preferentially directed towards cell membrane assembly. It also highlights the unique metabolic reprogramming of mutant IDH1 cells.
- Published
- 2017
95. EXTH-51. PI3K/mTOR INHIBITION LEADS TO REDUCTION IN 2HG PRODUCTION AND CELL PROLIFERATION IN IDH1 MUTANT CELLS
- Author
-
Georgios Batsios, Russell O. Pieper, Sabrina M. Ronen, Joanna J. Phillips, and Pavithra Viswanath
- Subjects
Cancer Research ,Voxtalisib ,Cell growth ,Chemistry ,Cell ,Mutant ,Molecular biology ,Glutamine ,Abstracts ,medicine.anatomical_structure ,Isocitrate dehydrogenase ,Oncology ,medicine ,Neurology (clinical) ,PI3K/AKT/mTOR pathway ,Astrocyte - Abstract
Mutations in isocitrate dehydrogenase (IDH1) drive tumorigenesis in 70–90% of low-grade gliomas and secondary glioblastomas. The mutant IDH1 enzyme produces the oncometabolite 2-hydroxyglutarate (2HG), which, in addition to driving tumorigenesis, also induces significant metabolic reprogramming. Dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibition is one of the therapeutic options under consideration for mutant IDH1 gliomas. The goal of the current study was to investigate the effect of one such inhibitor, namely XL765 (Voxtalisib), on mutant IDH1 glioma cells. We used two cell models genetically-engineered to express mutant IDH1: a U87 glioblastoma-based model and an immortalized normal human astrocyte (NHA)-based model. In both of our models we found that XL765 significantly inhibited cell proliferation to ~50% following treatment with 12uM and 32uM for 24h and 72h for U87 and NHA respectively. We then used magnetic resonance spectroscopy (MRS) to investigate the impact of treatment on cell metabolism. Using 1H-MRS, we observed that XL765 induced a significant ~70% and ~50% reduction in steady-state levels of 2HG and glutamate respectively in U87 while in NHA the drop was ~90% and ~70% for 2HG and glutamate respectively. Using 13C-MRS, we observed a reduction in flux from [1-13C]-glucose to [4-13C]-2HG and to [4-13C]-glutamate, indicating reduced flux to the tricarboxylic acid (TCA) cycle in both models. We also observed a reduction of [3-13C]-glutamine flux to [3-13C]-2HG and [3-13C]-glutamate in the treatment group. Finally, the treatment group presented reduced glucose and glutamine uptake from the media compared to control. Collectively, our results indicate that treatment with a PI3K/mTOR inhibitor is associated with response in mutant IDH1 models that is accompanied by inhibition in the synthesis of 2HG and glutamate from both glucose and glutamine. The metabolic changes are detectably by MRS and could be used as biomarkers of response for patients undergoing treatment with PI3K/mTOR inhibitors.
- Published
- 2017
96. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
- Author
-
Jose L. Izquierdo-Garcia, Myriam M. Chaumeil, Larry Cai, Michael D. Blough, J. Gregory Cairncross, Pavithra Viswanath, Pia Eriksson, H. Artee Luchman, Joanna J. Phillips, Samuel Weiss, Russell O. Pieper, Sabrina M. Ronen, and Marina Radoul
- Subjects
Cancer Research ,Magnetic Resonance Spectroscopy ,Pyruvate dehydrogenase kinase ,Mutant ,Down-Regulation ,Glutamic Acid ,Pyruvate Dehydrogenase Complex ,Biology ,Pyruvate dehydrogenase phosphatase ,Article ,Glutarates ,Cell Line, Tumor ,medicine ,Humans ,Pyruvates ,Cell Proliferation ,Dichloroacetic Acid ,Cell growth ,Pyruvate dehydrogenase complex ,Molecular biology ,Isocitrate Dehydrogenase ,medicine.anatomical_structure ,Isocitrate dehydrogenase ,Oncology ,Cell culture ,Astrocytes ,Mutation ,Glioblastoma ,Astrocyte - Abstract
Mutant isocitrate dehydrogenase 1 (IDH1) catalyzes the production of 2-hydroxyglutarate but also elicits additional metabolic changes. Levels of both glutamate and pyruvate dehydrogenase (PDH) activity have been shown to be affected in U87 glioblastoma cells or normal human astrocyte (NHA) cells expressing mutant IDH1, as compared with cells expressing wild-type IDH1. In this study, we show how these phenomena are linked through the effects of IDH1 mutation, which also reprograms pyruvate metabolism. Reduced PDH activity in U87 glioblastoma and NHA IDH1 mutant cells was associated with relative increases in PDH inhibitory phosphorylation, expression of pyruvate dehydrogenase kinase-3, and levels of hypoxia inducible factor-1α. PDH activity was monitored in these cells by hyperpolarized 13C-magnetic resonance spectroscopy (13C-MRS), which revealed a reduction in metabolism of hyperpolarized 2-13C-pyruvate to 5-13C-glutamate, relative to cells expressing wild-type IDH1. 13C-MRS also revealed a reduction in glucose flux to glutamate in IDH1 mutant cells. Notably, pharmacological activation of PDH by cell exposure to dichloroacetate (DCA) increased production of hyperpolarized 5-13C-glutamate in IDH1 mutant cells. Furthermore, DCA treatment also abrogated the clonogenic advantage conferred by IDH1 mutation. Using patient-derived mutant IDH1 neurosphere models, we showed that PDH activity was essential for cell proliferation. Taken together, our results established that the IDH1 mutation induces an MRS-detectable reprogramming of pyruvate metabolism, which is essential for cell proliferation and clonogenicity, with immediate therapeutic implications. Cancer Res; 75(15); 2999–3009. ©2015 AACR.
- Published
- 2015
97. Changes in Pyruvate Metabolism Detected by Magnetic Resonance Imaging Are Linked to DNA Damage and Serve as a Sensor of Temozolomide Response in Glioblastoma Cells
- Author
-
Motokazu Ito, Ilwoo Park, Llewellyn E. Jalbert, Sabrina M. Ronen, Myriam M. Chaumeil, Joydeep Mukherjee, Sarah J. Nelson, Russell O. Pieper, and Karin M.L. Gaensler
- Subjects
Thyroid Hormones ,Cancer Research ,DNA Repair ,DNA damage ,DNA repair ,Oncology and Carcinogenesis ,Gene Expression ,Apoptosis ,PKM2 ,Biology ,Article ,Cell Line ,chemistry.chemical_compound ,Rare Diseases ,Cell Line, Tumor ,Lactate dehydrogenase ,Pyruvic Acid ,DNA Repair Protein ,Biomarkers, Tumor ,Temozolomide ,2.1 Biological and endogenous factors ,Humans ,Glycolysis ,Oncology & Carcinogenesis ,CHEK1 ,Aetiology ,Cancer ,Tumor ,L-Lactate Dehydrogenase ,Neurosciences ,Membrane Proteins ,Methyltransferases ,NAD ,Magnetic Resonance Imaging ,Molecular biology ,Brain Disorders ,Brain Cancer ,Dacarbazine ,Oncology ,chemistry ,Checkpoint Kinase 1 ,Cancer research ,Carrier Proteins ,Glioblastoma ,Protein Kinases ,Biomarkers ,Pyruvate kinase ,DNA Damage - Abstract
Recent findings show that exposure to temozolomide (TMZ), a DNA-damaging drug used to treat glioblastoma (GBM), can suppress the conversion of pyruvate to lactate. To understand the mechanistic basis for this effect and its potential utility as a TMZ response biomarker, we compared the response of isogenic GBM cell populations differing only in expression of the DNA repair protein methyltransferase (MGMT), a TMZ-sensitivity determinant, after exposure to TMZ in vitro and in vivo. Hyperpolarized [1-(13)C]-pyruvate–based MRI was used to monitor temporal effects on pyruvate metabolism in parallel with DNA-damage responses and tumor cell growth. TMZ exposure decreased conversion of pyruvate to lactate only in MGMT-deficient cells. This effect coincided temporally with TMZ-induced increases in levels of the DNA-damage response protein pChk1. Changes in pyruvate to lactate conversion triggered by TMZ preceded tumor growth suppression and were not associated with changes in levels of NADH or lactate dehydrogenase activity in tumors. Instead, they were associated with a TMZ-induced decrease in the expression and activity of pyruvate kinase PKM2, a glycolytic enzyme that indirectly controls pyruvate metabolism. PKM2 silencing decreased PK activity, intracellular lactate levels, and conversion of pyruvate to lactate in the same manner as TMZ, and Chk1 silencing blocked the TMZ-induced decrease in PKM2 expression. Overall, our findings showed how TMZ-induced DNA damage is linked through PKM2 to changes in pyruvate metabolism, and how these changes can be exploited by MRI methods as an early sensor of TMZ therapeutic response. Cancer Res; 74(23); 7115–24. ©2014 AACR.
- Published
- 2014
98. Autophagy-Dependent Shuttling of TBC1D5 Controls Plasma Membrane Translocation of GLUT1 and Glucose Uptake
- Author
-
Jayanta Debnath, Andrew M. Leidal, Srirupa Roy, Jordan Ye, and Sabrina M. Ronen
- Subjects
0301 basic medicine ,Retromer ,Glucose uptake ,Vesicular Transport Proteins ,Autophagy-Related Protein 7 ,Medical and Health Sciences ,Autophagy-Related Protein 5 ,Mice ,Glucose Transporter Type 1 ,GTPase-Activating Proteins ,glycolysis ,Biological Sciences ,Cell biology ,Protein Transport ,RNA Interference ,Female ,retromer ,Glycolysis ,Microtubule-Associated Proteins ,Intracellular ,Signal Transduction ,autophagy ,Endosome ,Physiological ,Endosomes ,Biology ,Transfection ,Stress ,Article ,03 medical and health sciences ,Stress, Physiological ,Autophagy ,Animals ,Humans ,Molecular Biology ,Cell Membrane ,Glucose transporter ,Autophagosomes ,Biological Transport ,Cell Biology ,Fibroblasts ,Autophagic Punctum ,carbohydrates (lipids) ,Retromer complex ,Kinetics ,030104 developmental biology ,Glucose ,HEK293 Cells ,biology.protein ,GLUT1 ,Generic health relevance ,Lysosomes ,Developmental Biology - Abstract
Autophagy traditionally sustains metabolism in stressed cells via promoting intracellular catabolism and nutrient recycling. Here, we demonstrate that in response to stresses requiring increased glycolytic demand, the core autophagy machinery also facilitates glucose uptake and glycolytic flux by promoting cell surface expression of the glucose transporter Glut1/Slc2a1. During metabolic stress, LC3+ autophagic compartments bind and sequester the RabGAP protein TBC1D5 away from its inhibitory interactions with the retromer complex, thereby enabling retromer recruitment to endosome membranes and Glut1 plasma membrane translocation. In contrast, TBC1D5 inhibitory interactions with the retromer are maintained in autophagy-deficient cells, leading to Glut1 mis-sorting into endolysosomal compartments. Furthermore, TBC1D5 depletion in autophagy deficient cells rescues retromer recruitment to endosomal membranes and Glut1 surface recycling. Hence, TBC1D5 shuttling to autophagosomes during metabolic stress facilitates retromer-dependent Glut1 trafficking. Overall, our results illuminate key interconnections between the autophagy and endosomal pathways dictating Glut1 trafficking and extracellular nutrient uptake.
- Published
- 2017
99. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma
- Author
-
Marram P. Olson, Jason C. Crane, Llewellyn E. Jalbert, Mitchel S. Berger, Adam Elkhaled, Susan M. Chang, John Kurhanewicz, Joanna J. Phillips, Aurelia Alvina Williams, Sarah J. Nelson, Evan Neill, Annette M. Molinaro, and Sabrina M. Ronen
- Subjects
Male ,0301 basic medicine ,IDH1 ,Biopsy ,Article ,03 medical and health sciences ,Rare Diseases ,Clinical Research ,In vivo ,Glioma ,Genetics ,medicine ,Humans ,Metabolomics ,Cancer ,Neoplasm Staging ,Multidisciplinary ,medicine.diagnostic_test ,Brain Neoplasms ,business.industry ,Neurosciences ,Astrocytoma ,medicine.disease ,Isocitrate Dehydrogenase ,Brain Disorders ,3. Good health ,Brain Cancer ,Orphan Drug ,030104 developmental biology ,Isocitrate dehydrogenase ,Mutation ,Disease Progression ,Metabolome ,Cancer research ,Female ,Oligodendroglioma ,Neoplasm Grading ,business ,Ex vivo - Abstract
Infiltrating low grade gliomas (LGGs) are heterogeneous in their behavior and the strategies used for clinical management are highly variable. A key factor in clinical decision-making is that patients with mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) oncogenes are more likely to have a favorable outcome and be sensitive to treatment. Because of their relatively long overall median survival, more aggressive treatments are typically reserved for patients that have undergone malignant progression (MP) to an anaplastic glioma or secondary glioblastoma (GBM). In the current study, ex vivo metabolic profiles of image-guided tissue samples obtained from patients with newly diagnosed and recurrent LGG were investigated using proton high-resolution magic angle spinning spectroscopy (1H HR-MAS). Distinct spectral profiles were observed for lesions with IDH-mutated genotypes, between astrocytoma and oligodendroglioma histologies, as well as for tumors that had undergone MP. Levels of 2-hydroxyglutarate (2HG) were correlated with increased mitotic activity, axonal disruption, vascular neoplasia, and with several brain metabolites including the choline species, glutamate, glutathione, and GABA. The information obtained in this study may be used to develop strategies for in vivo characterization of infiltrative glioma, in order to improve disease stratification and to assist in monitoring response to therapy.
- Published
- 2017
100. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance
- Author
-
Diego Carrera, Brandyn A. Castro, Alan Nguyen, Joanna J. Phillips, Sabrina M. Ronen, Suneil K. Koliwad, Arman Jahangiri, Ankush Chandra, Maxim Sidorov, Smita Mascharak, Annette M. Molinaro, Michael De Lay, Pia Eriksson, Jeffrey Wagner, Patrick M. Flanigan, Jose Luiz Izquierdo Garcia, Josie Hayes, Manish K. Aghi, Garima Yagnik, and Ruby Kuang
- Subjects
0301 basic medicine ,Magnetic Resonance Spectroscopy ,genetic structures ,Glucose uptake ,Cell ,Nude ,Drug Resistance ,Angiogenesis Inhibitors ,Mitochondrion ,Oxidative Phosphorylation ,Mice ,Pyruvic Acid ,Glycolysis ,Cancer ,Tumor ,Glucose Transporter Type 3 ,General Medicine ,3. Good health ,Up-Regulation ,Bevacizumab ,medicine.anatomical_structure ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Biotechnology ,Research Article ,medicine.medical_specialty ,Cell Survival ,Mice, Nude ,Oxidative phosphorylation ,Biology ,Cell Line ,03 medical and health sciences ,Rare Diseases ,Internal medicine ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Glycogen synthase ,Glucose transporter ,eye diseases ,030104 developmental biology ,Endocrinology ,Glucose ,Drug Resistance, Neoplasm ,Cancer research ,biology.protein ,Neoplasm ,sense organs ,Glioblastoma ,Neoplasm Transplantation ,GLUT3 - Abstract
Clinical trials revealed limited response duration of glioblastomas to VEGF-neutralizing antibody bevacizumab. Thriving in the devascularized microenvironment occurring after antiangiogenic therapy requires tumor cell adaptation to decreased glucose, with 50% less glucose identified in bevacizumab-treated xenografts. Compared with bevacizumab-responsive xenograft cells, resistant cells exhibited increased glucose uptake, glycolysis, 13C NMR pyruvate to lactate conversion, and survival in low glucose. Glucose transporter 3 (GLUT3) was upregulated in bevacizumab-resistant versus sensitive xenografts and patient specimens in a HIF-1α-dependent manner. Resistant versus sensitive cell mitochondria in oxidative phosphorylation-selective conditions produced less ATP. Despite unchanged mitochondrial numbers, normoxic resistant cells had lower mitochondrial membrane potential than sensitive cells, confirming poorer mitochondrial health, but avoided the mitochondrial dysfunction of hypoxic sensitive cells. Thin-layer chromatography revealed increased triglycerides in bevacizumab-resistant versus sensitive xenografts, a change driven by mitochondrial stress. A glycogen synthase kinase-3β inhibitor suppressing GLUT3 transcription caused greater cell death in bevacizumab-resistant than -responsive cells. Overexpressing GLUT3 in tumor cells recapitulated bevacizumab-resistant cell features: survival and proliferation in low glucose, increased glycolysis, impaired oxidative phosphorylation, and rapid in vivo proliferation only slowed by bevacizumab to that of untreated bevacizumab-responsive tumors. Targeting GLUT3 or the increased glycolysis reliance in resistant tumors could unlock the potential of antiangiogenic treatments.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.